阅读说明：本技术 治疗癌症的vegfr-2 car免疫细胞 (The VEGFR-2 CAR immunocyte for the treatment of cancer ) 是由 巢立文 黄华友 田保民 玛尼·黛安·乌格 于 2018-01-04 设计创作，主要内容包括：提供了使用CAR治疗人类癌症的组合物和方法。本发明包括工程化的CAR(嵌合受体抗原)和表达对VEGFR具有高亲和力的此类CAR的基因修饰的免疫细胞。更具体地,细胞是识别实体瘤上VEGFR-2的CAR-T细胞,其用途,其组合物及其制备方法。本发明包括靶向肿瘤血管生成的治疗VEGFR-2依赖的癌症的治疗方法。嵌合抗原受体(CAR),其与VEGFR-2、VEGFR-2的表位或片段、或VEGFR-2的变体结合。(Provide the composition and method using CAR treatment human cancer.The present invention includes the immunocyte of the gene modification of the such CAR of the CAR (Chimerical receptor antigen) and expression of engineering to VEGFR with high-affinity.More specifically, cell is the CAR-T cell for identifying VEGFR-2 on solid tumor, purposes, its composition and preparation method thereof.The present invention includes the treatment method for the cancer that the treatment VEGFR-2 of target tumor angiogenesis is relied on.Chimeric antigen receptor (CAR), in conjunction with the variant of the epitope of VEGFR-2, VEGFR-2 or segment or VEGFR-2.)

1. Chimeric antigen receptor (CAR), in conjunction with the variant of the epitope of VEGFR-2, VEGFR-2 or segment or VEGFR-2.

2. CAR as described in claim 1, wherein the CAR includes for the single domain antibody or its piece in conjunction with VEGFR-2 Section.

3. CAR as claimed in claim 2, wherein the single domain antibody or its segment belong to Camelidae (Camelidae) kind.

4. the CAR as described in any claim in claims 1 to 3, wherein the CAR is in conjunction with the epitope of VEGFR-2.

5. CAR as claimed in claim 4, wherein the CAR is in conjunction with the epitope found in SEQ ID NO:1.

6. the CAR as described in any claim in claim 1 to 5, wherein the CAR includes complementary determining region (CDR) 1； CDR2 and/or CDR3, wherein at least one of CDR1, CDR and CDR3 are in conjunction with VEGFR-2.

7. the CAR as described in any claim in claim 1 to 6 is selected from wherein the CAR has comprising at least one The CDR of the sequence of SYAMG, AISWSDDSTYYANSVKG, HKSLQRPDEYTY and with combine VEGFR-2 sequence at least 70% The sequence of identity.

8. the CAR as described in any claim in claim 1 to 7, it includes the sequence of SEQ ID NO:78 or and SEQ The sequence of ID NO:78 at least 90% identity.

9. the CAR as described in any claim in claim 1 to 8, it includes spacer molecules, transmembrane region and one or more Cell signal structural domain, the cell signal structural domain are selected from people CD8- α albumen, people CD28 albumen, people CD3- ζ albumen, people FcRy albumen, CD27 albumen, OX40 albumen, people 4-IBB albumen, aforementioned any modified forms and any group above-mentioned It closes.

10. the CAR as described in any claim in claim 1 to 9, it includes be selected from SEQ ID NO:2-30 or its segment Or the sequence of variant.

11. the CAR as described in any claim in claim 1 to 9, it includes be selected from SEQ ID NO:2-30 or and SEQ ID NO:2-30 at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, the sequence of at least 93%, at least 94% or at least 95% identity, or the sequence substantially same with SEQ ID NO:2-30 Column.

12. CAR as described in claim 10 or 11, wherein the sequence includes the connector sequence selected from SEQ ID NO:54-69 Column.

13. CAR as claimed in claim 12, wherein the joint sequence can also include C-terminal cysteine.

14. CAR as claimed in claim 13, wherein the joint sequence includes GSEQKGGGEEDDGC or its variant.

15. immunocyte, it includes CAR described in any claim in claim 1 to 14.

16. immunocyte as claimed in claim 15, wherein the cell is T cell or cytokine-induced killer cell (CIK) cell.

17. the immunocyte as described in claim 15 or 16 also includes at least the 2nd CAR.

It also include optionally hyperactive 18. the immunocyte as described in any claim in claim 15 to 17 Transposons/transposase system.

19. immunocyte as claimed in claim 18, wherein the transposons/transposase system is sleeping beauty transposon stand/turn Seat enzyme system.

20. the immunocyte as described in claim 18 or 19 the, wherein transposons/transposase system is SB100X swivel base Son/transposase system.

21. the immunocyte as described in any claim in claim 15 to 20 also includes suicide gene.

22. the immunocyte as described in any claim in claim 15 to 21, it is formulated into comprising pharmaceutical carrier, dilute Release the composition of agent and/or excipient.

23. the nucleic acid molecules of encoding chimeric antigen receptor (CAR), wherein the CAR includes VEGFR-2 bound fraction and is immunized thin Born of the same parents' activating part, wherein the VEGFR-2 bound fraction is in conjunction with VEGFR-2 or its variant or segment.

24. nucleic acid molecules as claimed in claim 23, wherein the VEGFR-2 bound fraction include for VEGFR-2 or The variant of VEGFR-2 or the monoclonal antibody of segment or its antigen-binding portion thereof.

25. nucleic acid molecules as claimed in claim 24, wherein the VEGFR-2 bound fraction includes the monoclonal antibody Variable region.

26. the nucleic acid molecules as described in any claim in claim 23 to 25, wherein the immune cell activation part Include the T cell signal domain in any one or more following albumen: people CD8- α albumen, people CD28 albumen, people's CD3- ζ egg White, people FcRy albumen, CD27 albumen, OX40 albumen, people 4-IBB albumen and its variant or segment.

27. the nucleic acid molecules as described in any claim in claim 23 to 26, it includes in SEQ ID NO:31-53 extremely The nucleic acid sequence of polypeptide of one of few nucleic acid sequence and/or coding in conjunction with the sequence of SEQ ID NO:1.

28. the nucleic acid molecules of the nucleotide sequence of one or two polypeptide chain comprising encoding chimeric antigen receptor (CAR), wherein The CAR successively includes from the end N- to the end C-:

I) the antigen binding single domain antibody of VEGFR-2 specificity；

Ii) transmembrane domain；

Iii) costimulation polypeptide, wherein the costimulation polypeptide is 4-1BB polypeptide and/or OX-40 polypeptide；And

Iv) intracellular signaling domain.

29. nucleic acid molecules as claimed in claim 28, wherein the first polypeptide is included in the single domain antibody and the cross-film knot The hinge area being inserted between structure domain.

30. nucleic acid molecules as claimed in claim 29, wherein the hinge area is Immunoglobulin IgG hinge area or is derived from The hinge of CD8.

31. the nucleic acid molecules as described in any claim in claim 28 to 30, wherein the intracellular signaling domain Include immunity receptor Tyrosine Activating Motifs (ITAM).

32. nucleic acid molecules as claimed in claim 31, wherein the intracellular signaling domain comprising ITAM is selected from CD3- ζ And ZAP70.

33. the nucleic acid molecules as described in any claim in claim 28 to 32, wherein the nucleotide sequence and T cell Specificity promoter is operably connected.

34. the nucleic acid molecules as described in any claim in claim 28 to 33, wherein the nucleotide sequence and NK are thin Born of the same parents' specificity promoter is operably connected.

35. nucleic acid molecules described in claim 34, it includes SEQ ID NO:79.

36. the Chimeric antigen receptor (CAR) of the nucleic acid sequence encoding as described in any claim in claim 25 to 35.

37. CAR as claimed in claim 36, it includes amino acid sequences any in SEQ ID NO:2-38.

38. carrier, it includes nucleic acid molecules described in any claim in claim 25 to 35.

39. host cell expresses nucleic acid molecules or claim 28 described in any claim in claim 25 to 35 Or CAR described in 29.

40. host cell as claimed in claim 40, wherein the host cell is immunocyte.

41. host cell as claimed in claim 41, wherein the host cell is selected from killing for T cell and cytokine induction Hurt CIK cell.

42. the host cell as described in any claim in claim 40 to 42 also includes at least the 2nd CAR.

It also include optionally hyperactive 43. the host cell as described in any claim in claim 40 to 43 Transposons/transposase system.

44. host cell as claimed in claim 44, wherein the transposons/transposase system is sleeping beauty transposon stand/turn Seat enzyme system.

45. the host cell as described in claim 44 or 45 the, wherein transposons/transposase system is SB100X swivel base Son/transposase system.

46. the host cell as described in any claim in claim 40 to 46 also includes suicide gene.

47. cell mass, it includes host cells described in any claim at least one claim 40 to 47.

48. pharmaceutical composition, it includes immunocyte described in any claim in claim 15 to 22 or claims Host cell described in any claim in 40 to 47.

49. the method for treating or preventing mammalian cancer, the method includes to effectively treat or prevent the mammal The amount of cancer is given immunocyte described in any claim or right in claim 15 to 22 to the mammal and is wanted Seek host cell described in any claim in 40 to 47.

50. method as claimed in claim 50, wherein the cancer is the cancer of VEGF expression R-2.

51. the method as described in claim 50 or 51, wherein the cancer is solid tumor.

52. reducing the method that blood vessels in tumors generates, the method includes to effectively reduce the amount of angiogenesis to the lactation Animal gives in claim 15 to 22 any right in immunocyte described in any claim or claim 40 to 47 It is required that the host cell.

53.CAR box, have the structure comprising signal peptide-VHH-CD8 hinge-CD28-4-1BB-CD3 ζ-T2A-EGFRt and Nucleic acid sequence with SEQ ID NO:79.

54.CAR box has structure and tool comprising signal peptide-VHH-CD8 hinge-CD28-4-1BB-CD3 ζ-T2A-EGFRt There is the amino acid sequence of SEQ ID NO:78.

55. human T-cell, it includes the nucleic acid sequences of encoding chimeric antigen receptor (CAR), wherein the CAR is anti-comprising VEGFR-2 Former binding structural domain, wherein the CAR also includes transmembrane domain, 4-1BB costimulatory signal region and CD3 ζ signal domain, Wherein the T cell is derived from the people with cancer.

56. human T-cell as claimed in claim 56, wherein using selected from antivirotic, chemotherapy, radiation, immune suppression The mode of preparation and antibody separates the human T-cell to before ruling treatment by men from the blood sample obtained by people.

Invention field

The present invention relates to immunotherapy for cancer, more particularly relate to the composition and method for the treatment of human cancer.This Invention includes that the gene of the such CAR of the CAR (Chimerical receptor antigen) and expression of engineering to VEGFR with high-affinity is repaired The immunocyte of decorations.More specifically, cell be identify solid tumor on VEGFR-2 CAR-T cell, purposes, its composition and Preparation method.The present invention includes the treatment method for the cancer that the treatment VEGFR-2 of target tumor angiogenesis is relied on.

Background of invention

Immune system shows huge hope in terms for the treatment of malignant tumor.In addition in reactivation tumor microenvironment Except the checkpoint inhibitor of existing T cell, Chimeric antigen receptor (CAR)-T cell of external source F-duction is in leukemia treating Clinical test in provide response full of hope.

Angiogenesis is the process of new vascularization and is required beyond certain size to tumour growth.Blood vessel is raw At the growth and transfer for promoting entity tumor.Tumors secrete angiogenic factors vascular endothelial growth factor (VEGF), By with vascular endothelial growth factor receptor (VEGFR) combination in part endothelial cell.

Vascular endothelial growth factor, VEGF are endothelial cell specific mitogen.Because by specificity promotion The proliferation of chrotoplast and play the role of angiogenesis inducing agents, it is unique in growth factor.Pass through its high-affinity Receptor is come including mediating the biological response of VEGF, the receptor selectively to express during embry ogenesis and during tumour is formed On chrotoplast.Vascular endothelial growth factor is raw by adjusting vascular development, angiogenesis and lymphatic vessel in conjunction with many receptors At.The migration of recruitment and monocyte and macrophage for candidate stem cell, VEGFR-1 are required.VEGFR-2 tune It saves function of vascular endothelium and VEGFR-3 adjusts lymphatic endothelium function.

It needs using Tumor Angiongesis as the composition and method of the treatment or prevention cancer of target.The demands such as this include making Solid tumor is treated with the CAR with clinical activity, the VEGFR-2 that the CAR identification is expressed on tumour cell is to help to control The relevant angiogenesis of tumour processed, to attempt limitation/reduction cancer progression/growth.

Summary of the invention

Kinds of tumors VEGF expression R-2.This document describes CAR the and CAR-T cells of the tumour of targeted expression VEGFR-2. The use that the CAR and CAR-T cell of anti-VEGFR-2 provided in this article has inhibition/reduction angiogenesis and tumour is induced to change in quality On the way.

The CAR of solid tumor is targeted the present invention provides engineering.On the one hand, genetically engineered T cell is allowed with generating The albumen of the expression CAR of differential protein (antigen) on T cell tumor cell.Then before being used to treat in the lab The CAR-T cell growth for being engineered these.Other aspects, CAR as described herein have high parent to the cancer that VEGFR-2 is relied on And power.The unique specificity of CAR as described herein comes from the scFv that the CAR of engineering is replaced using sdAbs (single domain antibody).By Small in its size, this provides higher affinity.Such antibody also has the propensity and biophysics for being easy to refolding Stability.In addition, they can identify the non-accessible epitope of conventional antibody and can be engineered.

Certain aspects of the invention are the human T-cells of the nucleic acid sequence comprising encoding chimeric antigen receptor (CAR), wherein institute State CAR include VEGFR-2 binding structural domain, wherein the CAR also include transmembrane domain, 4-1BB costimulatory signal area and CD3 ζ signal domain, wherein the T cell is derived from the people with cancer.In some aspects, the cancer of VEGF expression R-2 is treated Disease.

As described herein in some terms, the sdAbs being used in CAR and CAR-T cell is the white horse with a black mane of VEGFR-2 specificity Camelidae single domain antibody.In some aspects, sdAbs is VEGFR-2 and its segment or its variant specificity.

CAR construct of the invention may include separation or purifying antibody or its segment, the antibody or its segment Comprising one of SEQ ID NO:2-30 sequence, or with its have at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94% or at least 95% identity Sequence, or the sequence substantially same with it, the antibody or its segment are with or without joint sequence.In some aspects, connector Sequence may include terminal cysteine useful to chemical bonding in some aspects.

The joint sequence for being suitable for single domain antibody of the invention can be selected from SEQ ID NO:54-65.In some aspects, connector Sequence can also include C-terminal cysteine, such as SEQ ID NO:66-69.It can be used herein similar to these joint sequences Sequence.

In some aspects, the immunocyte for expressing CAR as described herein is provided.Immunocyte is usually T cell or CIK Cell is but it is also possible to be natural kill (NK) cell, cytotoxic T lymphocyte (CTL) and regulatory T cells.

It is as described herein in some terms, providing the method for being used to prepare the CAR-T of VEGFR-2 specificity.In certain sides Face, the method can be viral or non-viral.More specifically, method in certain aspects is comprising transposons Non-viral method.

The present invention provides the isolated nucleic acid sequences of encoding chimeric antigen receptor (CAR), wherein the CAR includes antigen Binding structural domain, transmembrane domain, one or more costimulatory signal areas and CD3 ζ signal domain, the antigen binding knot Structure domain is the sdAb in conjunction with VEGFR-2 and its variant, segment and defined epitope.On the one hand, the nucleic acid sequence for encoding CAR includes The nucleic acid sequence of SEQ ID NO:79.In this non-limiting example, CAR includes AB1 (SEQ ID NO:2).

On the one hand, the antigen-binding domains in CAR are antibody or its antigen-binding fragment.In general, antigen-binding fragment It is single domain antibody or its segment.

On the one hand, the sdAb in CAR is in conjunction with the solid tumor of VEGF expression R-2.

On the one hand, the costimulatory signal area in CAR includes the intracellular domain of costimulatory molecules selected from the following: CD27, CD28,4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, ligand and any combination thereof with CD83 specific binding.

The present invention also provides isolated CAR, and it includes antigen-binding domains, transmembrane domain, costimulatory signal areas With CD3 ζ signal domain.

The present invention also provides the cells of the nucleic acid sequence comprising encoding CAR, wherein the CAR includes antigen binding knot Structure domain, transmembrane domain, costimulatory signal area and CD3 ζ signal domain.

On the one hand, the immunocyte comprising CAR is selected from T cell, natural kill (NK) cell, CIK cell, cytotoxic T Lymphocyte (CTL) and regulatory T cells.

The present invention also provides the carriers of the nucleic acid sequence comprising encoding CAR, wherein the CAR includes antigen binding knot Structure domain, costimulatory signal area and CD3 ζ signal domain.

The present invention also provides the methods for reducing tumour growth in mammal.On the one hand, this method includes to the food in one's mouth Newborn animal gives a effective amount of gene modification to express the cell of CAR, wherein the CAR includes antigen-binding domains, altogether thorn Energizing signal area and CD3 ζ signal domain, wherein the antigen-binding domains are the sdAb of specific recognition VEGFR-2.

The present invention also provides the methods for reducing angiogenesis relevant to tumour in mammal.On the one hand, should Method includes the cell for giving a effective amount of gene modification to mammal to express CAR, wherein the CAR includes antigen knot Structural domain, costimulatory signal area and CD3 ζ signal domain are closed, wherein the antigen-binding domains are specific recognitions The sdAb of VEGFR-2.

The method of mammal the invention also includes treatment with tumour relevant to VEGFR-2 expression raising.One side Face, this method includes giving a effective amount of gene modification to mammal to express the cell of CAR, to treat mammal, Wherein the CAR includes sdAb, costimulatory signal area and the CD3 ζ signal domain of VEGFR-2 specificity.

On the one hand, cell is Autologous T cells.

On the other hand, cell is allogeneic T cells.

The invention also includes generate to continue existing genetically engineered T cell group's in the people for being diagnosed with cancer Method.On the one hand, this method includes that the genetically engineered T cell to express CAR is given to people, wherein the CAR includes Antigen-binding domains, costimulatory signal area and the CD3 ζ signal domain of VEGFR-2 specificity, wherein persistently being deposited after giving Genetically engineered T cell group in people persistently exist at least one moon.

On the one hand, it is at least one thin to the T of people selected from giving comprising selecting to continue existing genetically engineered T cell group Born of the same parents give to the cell of the filial generation of T cell of people and combinations thereof.

On the one hand, continuing existing genetically engineered T cell group includes memory T cell.

On the one hand, continue existing genetically engineered T cell group persistently to exist at least three months in people after giving. On the other hand, continue existing genetically engineered T cell group persistently to exist at least four months, five in people after giving The moon, six months, seven months, eight months, nine months, ten months, 11 months, 12 months, 2 years or 3 years.

The present invention also provides the methods for the T cell group that amplification gene is engineered in the people for being diagnosed with cancer.One Aspect, this method includes that the genetically engineered T cell to express CAR is given to people, wherein the CAR includes VEGFR-2 special Property sdAb, costimulatory signal area and CD3 ζ signal domain, wherein the genetically engineered T cell given produces in people Raw progeny T cells group.

It on the one hand, include memory T cell in people's generation of neutrons T cell.

On the one hand, T cell is Autologous T cells or allogeneic T cells.

On the one hand, immunocyte is CIK cell, can be self or allogeneic.

On the other hand, people is resistant at least one chemotherapeutant.

On the one hand, cancer is any cancer of VEGF expression R-2 and its variant or epitope.Such cancer includes but unlimited In pancreas, mammary gland, Colon and rectum, lung, stomach, ovary and bladder.

On the one hand, progeny T cells group persistently exists at least three months in people after giving.On the other hand, progeny T cells Group after giving in people persistently exist at least four months, five months, six months, seven months, eight months, nine months, ten months, 11 months, 12 months, 2 years or 3 years.

Certain aspects of the invention are Chimeric antigen receptor (CAR), with the epitope of VEGFR-2, VEGFR-2 or its The variant of segment or VEGFR-2 combine.Other aspects are the funtion parts of CAR of the invention, retain the part biological of CAR Activity.

In some terms, CAR includes for the single domain antibody or its segment in conjunction with VEGFR-2.Single domain antibody may include Sequence selected from SEQ ID No:2-30.

In some terms, single domain antibody or its segment belong to Camelidae (Camelidae) kind.

In some terms, CAR is in conjunction with the epitope of VEGFR-2.Such as, but not limited to, 8,378, No. 071 (its of U.S. Patent No. Disclosure is incorporated herein by reference in their entirety) described in epitope.

In some terms, CAR includes for the complementary determining region (CDR) 1 in conjunction with VEGFR-2；CDR2；And CDR3.

In some terms, CAR includes amino acid sequence:

[signal peptide-VHH-CD8 hinge-CD28-4-1BB-CD3 ζ-T2A-EGFRt],

In some terms, it includes SEQ ID NO:78 or its variant or segment or by SEQ ID NO:78 or its variant or piece Duan Zucheng such as has the sequence of at least 90% identity with it.VHH sequence includes AB1 (SEQ ID NO:2).SEQ ID NO:79 represents the nucleic acid sequence of coding CAR.

In some terms, CAR includes spacer molecule, transmembrane region and one or more cell signal structural domains, the cell letter Number structural domain be selected from people CD8- α albumen, people CD28 albumen, people CD3- ζ albumen, people FcRy albumen, CD27 albumen, OX40 albumen, People 4-IBB albumen, aforementioned any modified forms and any combination above-mentioned.

Some aspects are the immunocytes comprising CAR as described herein.Cell can be T cell or cell factor Killing (CIK) cell of induction.In some terms, immunocyte can also include at least the 2nd CAR.

In some terms, immunocyte includes transposons/transposase system of optionally hyperactive.In some terms, swivel base Son/transposase system is sleeping beauty transposon stand/transposase system.Other aspects, transposons/transposase system is SB100X swivel base Son/transposase system.

Other aspects, CAR immunocyte can also include suicide gene.

Other aspects provide immune thin as the CAR of the composition comprising pharmaceutical carrier, diluent and/or excipient Born of the same parents.The composition can be refrigerated, freezed or thawed.

Certain aspects of the invention are the nucleic acid molecules of encoding chimeric antigen receptor (CAR), wherein the CAR includes VEGFR-2 bound fraction and immune cell activation part, wherein the VEGFR-2 bound fraction and VEGFR-2 or its variant or Segment combines.

In some terms, VEGFR-2 bound fraction includes the single domain list of the variant for VEGFR-2 or VEGFR-2 or segment Clonal antibody or its antigen-binding portion thereof.In some terms, VEGFR-2 bound fraction includes the variable region of monoclonal antibody.

In some terms, immune cell activation part includes the T cell signal structure in any one or more following albumen Domain: people CD8- α albumen, people CD28 albumen, people CD3- ζ albumen, people FcRy albumen, CD27 albumen, OX40 albumen, people's 4-IBB egg Its variant of bletilla or segment.

Some aspects be comprising encoding chimeric antigen receptor (CAR) one or two polypeptide chain nucleotide sequence Nucleic acid molecules, wherein the CAR successively includes from N-terminal to C-terminal:

I) the antigen binding single domain antibody of VEGFR-2 specificity；

Ii) transmembrane domain；

Iii) costimulation polypeptide, wherein the costimulation polypeptide is 4-1BB polypeptide and/or OX-40 polypeptide；And

Iv) intracellular signaling domain.

In some terms, the first polypeptide includes the hinge area being inserted between single domain antibody and transmembrane domain.

In some terms, hinge area is Immunoglobulin IgG hinge area or the hinge derived from CD8.

In some terms, intracellular signaling domain includes immunity receptor Tyrosine Activating Motifs (ITAM).

In some terms, intracellular signaling domain includes the ITAM selected from CD3- ζ and ZAP70.

In some terms, nucleotide sequence is operably connected with T cell specificity promoter.

In some terms, nucleotide sequence is operably connected with NK cell specificity promotor.

Certain aspects of the invention are the Chimeric antigen receptors (CAR) by nucleic acid sequence encoding as disclosed herein.Certain A little aspects, CAR are VEGFR-2 specificity.

In some terms, CAR of the invention includes the amino acid sequence of SEQ ID NO:2-30, the amino acid sequence includes Retain its active segment and variant for combining VEGFR-2.

Some aspects are the carriers comprising nucleic acid molecules as described herein.In some terms, nucleic acid molecule encoding SEQ ID The polypeptide of NO:78.

Some aspects are expression nucleic acid molecules as described herein or the host cell of CAR.In some terms, host cell is Immunocyte.

In some terms, host cell is selected from T cell and cytokine-induced killer cell CIK cell, and in some terms, also It may include at least the 2nd CAR.

In some terms, host cell can also include transposons/transposase system of optionally hyperactive.Certain sides Face, transposons/transposase system are sleeping beauty transposon stand/transposase systems.Other aspects, transposons/transposase system are SB100X transposons/transposase system.

In some terms, host cell can also include suicide gene.

Some aspects are the cell masses comprising at least one host cell as described herein.

Some aspects are the pharmaceutical compositions comprising immunocyte as described herein or host cell.

Some aspects are the methods for treating or preventing the cancer of VEGF expression R-2 in mammal, and this method includes to have The amount that effect treats or prevents mammalian cancer gives immunocyte or host cell as described herein to the mammal. In some terms, tumour is solid tumor.In some terms, cancer is cancer of pancreas, breast cancer, colorectal cancer, lung cancer, gastric cancer, liver cell Cancer, oophoroma or bladder cancer.

Some aspects are the growth or reduction VEGF expression R-2 for reducing the tumour of VEGF expression R-2 in individual The method of the size of tumour, wherein this method includes giving the composition of the CAR-T comprising VEGFR-2 specificity.

Some aspects are the methods for the angiogenesis for reducing the tumour of VEGF expression R-2 in individual, wherein the party Method includes giving the composition of the CAR-T comprising VEGFR-2 specificity.

Other aspects of the present invention are as follows:

An aspect of of the present present invention is Chimeric antigen receptor (CAR), with the epitope or segment of VEGFR-2, VEGFR-2 or The variant of VEGFR-2 combines.

Another aspect of the present invention, CAR include for the single domain antibody or its segment in conjunction with VEGFR-2.

An aspect of of the present present invention, CAR include the single domain antibody or its segment of Camelidae (Camelidae) kind.

An aspect of of the present present invention, CAR is in conjunction with the epitope of VEGFR-2.

An aspect of of the present present invention, CAR is in conjunction with the epitope found in SEQ ID NO:1.

An aspect of of the present present invention, CAR include complementary determining region (CDR) 1；CDR2；And/or CDR3, wherein the CDR1, At least one of CDR2 and CDR3 are in conjunction with VEGFR-2.

An aspect of of the present present invention, CAR include the sequence of SEQ ID NO:78, or same with SEQ ID NO:78 at least 90% The sequence of property.

An aspect of of the present present invention, CAR also include spacer molecule, transmembrane region and one or more cell signal structural domains, institute State cell signal structural domain be selected from people CD8- α albumen, people CD28 albumen, people CD3- ζ albumen, people FcRy albumen, CD27 albumen, OX40 albumen, people 4-IBB albumen, aforementioned any modified forms and any combination above-mentioned.

An aspect of of the present present invention, CAR include the sequence selected from SEQ ID NO:2-30 or 31-53 and its variant and segment, Or with SEQ ID NO:2-30 or 31-53 at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, the sequence of at least 91%, at least 92%, at least 93%, at least 94% or at least 95% identity, or with SEQ ID Any substantially same sequence in NO:2-30 or SEQ ID NO:31-53.

An aspect of of the present present invention, CAR can also include any and its variant connector in SEQ ID NO:54-65 Sequence.

Certain aspects of the invention, CAR joint sequence can also include C-terminal cysteine, and in terms of other, connector Sequence is selected from SEQ ID NO:66-69.Sequence similar with these joint sequences can be used herein.For example, KK is suitable Any sequence of joint sequence and those sequences comprising SEQ ID NO:54-69.

Certain aspects of the invention, joint sequence include GSEQKGGGEEDDGC and its variant.

An aspect of of the present present invention is the immunocyte comprising CAR as described herein.

An aspect of of the present present invention, immunocyte are T cell or cytokine-induced killer cell (CIK) cell.

Another aspect of the present invention, immunocyte also include at least the 2nd CAR.

Certain aspects of the invention, immunocyte also include transposons/transposase system of optionally hyperactive.Certain A little aspects, transposons/transposase system is sleeping beauty transposon stand/transposase system.Other aspects, transposons/transposase system It is SB100X transposons/transposase system.

Certain aspects of the invention, immunocyte also include suicide gene.

Immunocyte comprising CAR of the invention is configured to comprising pharmaceutical carrier, diluent by certain aspects of the invention And/or the composition of excipient.

An aspect of of the present present invention is the nucleic acid molecules of encoding chimeric antigen receptor (CAR), wherein the CAR includes VEGFR- 2 bound fractions and immune cell activation part, wherein the VEGFR-2 bound fraction and VEGFR-2 or its variant or segment knot It closes.

Certain aspects of the invention, VEGFR-2 bound fraction include the variant or segment for VEGFR-2 or VEGFR-2 Monoclonal antibody or its antigen-binding portion thereof.In some terms, VEGFR-2 bound fraction includes the variable region of monoclonal antibody.

An aspect of of the present present invention, immune cell activation part include the T cell signal in following any one or more albumen Conducting structure domain: people CD8- α albumen, people CD28 albumen, people CD3- ζ albumen, people FcRy albumen, CD27 albumen, OX40 albumen, people 4-IBB albumen and its variant or segment.

An aspect of of the present present invention, nucleic acid molecules include at least one of SEQ ID NO:31-53 nucleic acid sequence and/or with The nucleic acid sequence that the sequence of SEQ ID NO:1 combines.

An aspect of of the present present invention is the nucleotides sequence of one or two polypeptide chain comprising encoding chimeric antigen receptor (CAR) The nucleic acid molecules of column, wherein the CAR successively includes from N-terminal to C-terminal:

I) the antigen binding single domain antibody of VEGFR-2 specificity；

Ii) transmembrane domain；

Iii) costimulation polypeptide, wherein the costimulation polypeptide is 4-1BB polypeptide and/or OX-40 polypeptide；With

Iv) intracellular signaling domain.

Certain aspects of the invention, the first polypeptide include the hinge area being inserted between single domain antibody and transmembrane domain.

Certain aspects of the invention, hinge area are Immunoglobulin IgG hinge area or the hinge derived from CD8.

Certain aspects of the invention, intracellular signaling domain include immunity receptor Tyrosine Activating Motifs (ITAM).

Certain aspects of the invention, intracellular signaling domain include the ITAM selected from CD3- ζ and ZAP70.

Certain aspects of the invention, nucleotide sequence are operably connected with T cell specificity promoter.

Certain aspects of the invention, nucleotide sequence are operably connected with NK cell specificity promotor.

Certain aspects of the invention, nucleic acid molecules include SEQ ID NO:79.

Certain aspects of the invention are the encoded Chimeric antigen receptors of nucleic acid sequence (CAR) by SEQ ID NO:79.

Certain aspects of the invention, CAR of the invention include any and its segment and variant in SEQ ID Nos:2-30 Amino acid sequence.

Certain aspects of the invention are the carriers comprising nucleic acid molecules any in SEQ ID NO:31-53.

An aspect of of the present present invention be express SEQ ID NO:79 nucleic acid molecules or SEQ ID NO:78 CAR host it is thin Born of the same parents.

Certain aspects of the invention, host cell are immunocytes.In some terms, host cell is selected from T cell and cell The killing CIK cell of factor induction.

Certain aspects of the invention, host cell also include at least the 2nd CAR.

In some terms, host cell of the invention also includes transposons/transposase system of optionally hyperactive.Certain A little aspects, transposons/transposase system is sleeping beauty transposon stand/transposase system.In some terms, transposons/transposase system It is SB100X transposons/transposase system.

Certain aspects of the invention, host cell of the invention further include suicide gene.

An aspect of of the present present invention is the cell mass comprising at least one host cell of the invention, and the host cell includes For the CAR of VEGFR-2.

An aspect of of the present present invention is the pharmaceutical composition comprising host cell or immunocyte, the host cell or immune Cell includes the CAR for VEGFR-2.

An aspect of of the present present invention is the method for treating or preventing mammalian cancer, and this method includes effectively to treat or in advance The amount of anti-mammalian cancer gives the immunocyte comprising the CAR for VEGFR-2 to the mammal or host is thin Born of the same parents.

Certain aspects of the invention, cancer are the cancers of VEGF expression R-2.

Certain aspects of the invention, cancer are solid tumors.

An aspect of of the present present invention is the method for reducing blood vessels in tumors and generating, and this method includes to effectively reduce angiogenesis Amount to mammal give comprising for VEGFR-2 CAR immunocyte or host cell.

Another aspect of the present invention is CAR box, has and includes signal peptide-VHH-CD8 hinge-CD28-4-1BB-CD3 The structure of ζ-T2A-EGFRt and the nucleic acid sequence with SEQ ID NO:79.

Another aspect of the present invention is CAR box, is had comprising signal peptide-VHH-CD8 hinge-CD28-4-1BB-CD3 ζ- The structure of T2A-EGFRt and the amino acid sequence with SEQ ID NO:78.

Certain aspects of the invention, CD8 α transmembrane domain, CD8 α hinge domain, 4-1BB costimulatory signal area and CD3 ζ signal domain can be by core shown in U.S. Patent No. 9,518,123 (the disclosure of which is integrally incorporated herein) Sequences code.

An aspect of of the present present invention is the human T-cell of the nucleic acid sequence comprising encoding chimeric antigen receptor (CAR), wherein institute Stating CAR includes VEGFR-2 antigen-binding domains, wherein the CAR also includes transmembrane domain, 4-1BB costimulatory signal area With CD3 ζ signal domain, wherein the T cell be derived from cancer people.In some terms, using selected from antivirotic, change The mode of therapy, radiation, immunosuppressor and antibody is learned to before ruling treatment by men, people T is separated from the blood sample obtained by people Cell.

Brief Description Of Drawings

When read in conjunction with the accompanying drawings, it is better understood with the described in detail below of typical pattern as described herein.For saying Typical aspect at present is shown in the attached drawings in the bright purpose of the present invention.It should be appreciated, however, that the present invention is not limited in attached drawing The elaborate scheme and means of shown aspect.

Fig. 1 shows AB1 (SEQ ID NO:2), AB2 (SEQ ID NO:11), AB3 (SEQ ID NO:19) and AB4 The size exclusion column chromatography of (SEQ ID NO:25).

Fig. 2 shows AB1 (SEQ ID NO:2), AB2 (SEQ ID NO:13), AB3 (SEQ ID NO:21) and AB4 The combination of (SEQ ID NO:27) and human VEGFR-3-2/Fc.

Fig. 3 shows the binding kinetics that AB1 (SEQ ID NO:7) is combined with human VEGFR-3-2/Fc.

Fig. 4 shows (a) single domain anti-VEGFR-2 antibody of the invention to the epitope mapping and (b) AB1 (SEQ of VEGFR-2 ID NO:2), the overlapping knot of the epitope of AB2 (SEQ ID NO:13), AB3 (SEQ ID NO:23) and AB4 (SEQ ID NO:27) It closes.

Fig. 5 shows AB1m (SEQ ID NO:9), AB2 (SEQ ID NO:13), AB3m (SEQ ID NO:23) and AB4 (SEQ ID NO:27) is combined to the antibody of VEGFR-1, VEGFR-2 and VEGFR-3 and cross reactivity.All 4 single domains are anti- Body is used to prepare urase (" DOS47 ") conjugate.Ability of these conjugates in conjunction with antigen VEGFR-2 is detected by ELISA And the ability of they and VEGFR-1 and VEGFR-3 cross reaction.All 4 kinds of antibody coupling matters all with the VEGFR2/ of recombination Fc is combined, and observes that yamma antibody coupling matter binding force is most strong (with the K measured in Fig. 2_DValue is consistent).All antibody are all aobvious Certain cross reactivity with VEGFR1/Fc is shown.Any antibody is to VEGFR3/Fc without detectable combination.

Fig. 6 shows AB1 (SEQ ID NO:2), AB2 (SEQ ID NO:13), AB3 (SEQ ID NO:23) and AB4 The result of the VEGF competitive assay of (SEQ ID NO:27).This test is carried out to evaluate whether antibody identifies close to VEGF knot Close the region of bag.Antibody-urase conjugate is mixed with VEGF with a variety of different molar ratios, is then measured to flat in ELISA The combination for the VEGFR2/Fc that plate was captured.Two kinds of human antibody conjugates (AB2- (SEQ ID NO:13) and AB3- (SEQ ID NO:21) DOS47) and the combination of VEGFR2 inhibited by VEGF, this shows that these antibody and VEGF are combined with overlapping site.Only The combination of AB1-DOS47 is minimum by VEGF effect, this shows that AB1 antibody and VEGF combine and is different site.Have Interest, the presence of VEGF enhance the combination of AB4-DOS47 and VEGFR2, this shows that AB4 antibody and VEGF/VEGFR2 are multiple The combination for closing object is got well than it is in conjunction with individual VEGFR2.

Fig. 7 is shown AB1 (SEQ ID NO:9)-DOS47 (A) and AB3 (SEQ ID with a variety of different molar ratios NO:23)-DOS47 (B) antibody-urase conjugate and 4 kinds of non-coupled antibody (SEQ ID NO:7,13,21 and 27) (or conduct The anti-CEACAM6 of negative control) in each mixing, then measure the knot to VEGFR2/Fc coated on ELISA plate It closes.The combination of each antibody-urase conjugate is all inhibited by corresponding non-coupled antibody.In addition, AB3- urase conjugate Inhibited by non-coupled AB2 antibody, this shows that both human antibodies share least partially overlapped epitope.Non-coupled AB3 antibody Also the combination of AB1-DOS47 is partially inhibited, although only in the case where very high molar ratio.

Fig. 8 shows antibody and the combination of antibody-urase conjugate and 293/KDR cell, and the 293/KDR cell is It is transfected the HEK293 cell to steadily VEGF expression R2 (KDR).With antibody or antibody-urase conjugate dyeing 293/ KDR cell and pass through Flow Cytometry Assay combine.Antibody A B1 (SEQ ID NO:6) and AB2 (SEQ ID NO:18) with The VEGFR2 expressed on 293/KDR cell is combined.

Fig. 9 show by crosslinking agent and by connect with cysteine activation after V21H1 (SEQ ID NO:3) antibody Deconvolution mass spectrum, it is shown that non-activated antibody, activated by a kind of antibody that crosslinking agent activates and by two kinds of crosslinking agents it is anti- The distribution of body.

Figure 10 shows V21H4 (SEQ ID NO:6) sample in the RP-HPLC chromatography at different renaturation time points.Blue Line: the sample when renaturation time 0, the component and renaturation buffer mixed moment that SP collects.Red line: 2 hours after mixing Renaturation time point.Green line: 2 hours renaturation samples after 4 hours renaturation samples and addition 1.2mM cysteine after the time 0 Product.Unfolded antibody was eluted at 12.513 minutes and folded antibody in elution in 10.958 minutes.

The screen of the intact proteins mass spectrum of V21H4 (the SEQ ID NO:6) sample of Figure 11: (A-C) from BiopharmaLynx Curtain snapshot.(A) the deconvolution spectrum of V21H4 (SEQ ID NO:6), display during renaturation by forming disulfide bond for half Cystamine is attached to C-terminal cysteine.(B) it with the deconvolution spectrum of V21H4 (SEQ ID NO:6) after 2mM TCEP reduction, shows Show the dissociation of the cystamine of C-terminal half.(C) with the deconvolution spectrum of the V21H4 restored after iodoacetamide subsequently, the end C is shown Cysteine is held to be close to the crosslinking agent of mercapto- activation.(D) it lives by crosslinking agent and by the connection with cysteine The deconvolution mass spectrum of V21H4 after change.By BM (PEG)₂The V21H4 antibody of activation generates the type of single activation.

The SDS- of Figure 12: (A) V21H1- (SEQ ID NO:3) DOS47 and V21H4- (SEQ ID NO:6) DOS47 PAGE.1, the band of 2 or 3 red-labels is number of clusters.Swimming lane 1: molecular weight ladder band.Swimming lane 2:HPU.Swimming lane 3 and 4:V21H1- DOS47.Swimming lane 5 and 6:V21H4-DOS47.(B) V21H1, V21H4, high-purity urease (HPU), V21H1-DOS47 and The size exclusion chromatography figure of V21H4-DOS47.

Biotin-V21H4 (SEQ ID NO:6) (black), V21H1- of Figure 13: (A) in conjunction with the VEGFR2/Fc of recombination The ELISA of DOS47 (SEQ ID NO:3) (green) and V21H4- (SEQ ID NO:6) DOS47 (red).Shown in the result is that The representative of 2-5 experiment is carried out to every a sample and shows as the average and SE of triplicate test sample.(B) biotin The combination of VEGFR2 expressed by-V21H4 (black) and V21H4-DOS47 (red) and 293/KDR cell.It is thin by streaming The quantization of born of the same parents' art combines.It is shown the result is that every a sample carry out 2-3 time test representative and show as duplicate test specimens The average and SE of product.(C) under different antibody/urase coupling ratio V21H4-DOS47 urease activity.Dotted line represents It is not coupled urease activity.(D) under different antibody-urase coupling ratio V21H4-DOS47 in conjunction with the VEGFR2/Fc of recombination ELISA.It is shown the result is that the representative tested twice to every a sample and showing as being averaged for duplicate test sample Several and SE.

The western blot of Figure 14: V21H4 (SEQ ID NO:6), HPU and V21H4- (SEQ ID NO:6) DOS47. Trace is detected with (A) anti-yamma antibody or (B) antiurease antibody.Swimming lane MW: molecular weight ladder band.Swimming lane 1:V21H4.Swimming lane 2: HPU.Swimming lane 3 and 4:V21H4-DOS47.

The HP urase (top) and V21H4- (SEQ ID NO:6) that Figure 15: (A) is handled by BiopharmaLynx software The Snipping Tool of original LC-MS (TIC) chromatogram of the trypsin digestion of DOS47 (bottom) sample.(B) binding site The Snipping Tool of the b/y fragmentography of UC824-VC136 the, with (top V21H4 peptide GGGEEDDGC modified by UC824-BM (PEG) 2 Portion) and by VC136-BM (PEG) 2 modify urase peptide LLCVSEATTVPLS (bottom) map.

Figure 16 is restrictive digestion figure, show endonuclease as a result, the segment (CAR box) of verifying insertion molecule Amount.

Figure 17 shows for determining the qPCR standard curve of slow virus titration.

Figure 18 shows the FACS detection of CAR expression.

Figure 19 shows target tumour cell and the LDH of the dissolution of CAR-T of the invention is measured, it is shown that external anti-vegf R- Validity of 2 CAR-T in pneumonocyte (NCI-H23), mammary glandular cell (ZR-75-30) and leukaemia cell (HL-60).CON-T It is the control T cell that do not transduce, CAR-T cell is VHH-CAR-T cell of the invention.

Figure 20 is the figure for showing the standard curve of IL-2 and IFN-γ measurement.

Figure 21 is the figure for showing the ELISA detection of IL-2 caused by control T cell and CAR-T cell of the invention.

Figure 22 is the figure for showing the ELISA detection of IFN-γ caused by control T cell and CAR-T cell of the invention.

Detailed description of the invention

The present invention relates to the compositions and method for treating cancer such as solid tumor.The present invention merge transduction T cell with Express the adoptive cell transfer of Chimeric antigen receptor (CAR).

T cell is gene modification steadily to express the CAR of desired targeting VEGFR-2, herein referred to as CAR T cell Or the T cell of CAR modification.Cell is through gene modification steadily to express novel antibody knot as described herein on the surface thereof Structural domain is closed, this give novel VEGFR-2 antigentic specificities.

In one embodiment, CAR of the invention includes the extracellular domain with antigen recognizing structural domain, transmembrane structure Domain and cytoplasmic domain.In one embodiment, using natively transmembrane domain relevant to one of CAR structural domain.In In another embodiment, transmembrane domain can be selected or modified by amino acid substitution.As for cytoplasmic domain, Neng Goushe Count CAR of the invention alone and include CD28 and/or 4-1BB signal domain or with can be used in CAR of the invention it is any its He combines desired cytoplasmic domain.In one embodiment, the cytoplasmic domain of CAR can be designed also to include The signal domain of CD3 ζ.For example, the cytoplasmic domain of CAR can include but is not limited to CD3 ζ, 4-1BB and CD28 signal mode Block and combinations thereof.Therefore, the present invention provides CAR T cell and its treats the cancer of VEGF expression R-2 for sex therapy of adopting Method.

It in one embodiment, can be by will include that the slow virus carrier of desired CAR is introduced into cell and generates this hair Bright CAR T cell, the CAR for example believe comprising anti-VEGFR-2, CD8 α hinge and transmembrane domain, people 4-1BB and CD3 ζ The CAR of number structural domain.CAR T cell of the invention can replicate in vivo, cause can long-term existence so as to causing to hold Continuous tumour control.

In addition, the T cell of the expression CAR of gene modification is used for cancer patient using lymphocyte infusion or in suffering from cancer The treatment of disease risk patient.Preferably, self lymphocyte infusion is used in treatment.Use method described herein and ability The self PBMC that well-known method activation and amplification are collected from patient's body in need for the treatment of in domain, is then fed back To patient.

The present invention includes using the T that can express the anti-VEGFR-2 CAR comprising CD3 ζ and 4-1BB costimulation structural domain Cell (also referred to as CART/VEGFR-2T cell).CART/VEGFR-2T cell of the invention can carry out steady T in vivo Cell amplification.

Definition

Unless otherwise explained, otherwise all technical and scientific terms used herein have with it is of the art general The logical identical meaning of the normally understood meaning of technical staff.The definition of essential term can be in Oxford in molecular biology The gene V (Genes V) 1994 (ISBN 0-19-854287-9) of Benjamin Lewin published by University Press； Molecular biology encyclopedia (the The of the Kendrew published by Blackwell Science Ltd. et al. (editor) Encyclopedia of Molecular Biology)1994(ISBN 0-632-02182-9)；And VCH Publisher Inc. the molecular biology and biotechnology of the Robert A.Meyers (editor) published: comprehensive desk reference (Molecular Biology and Biotechnology:a Comprehensive Desk Reference)1995(ISBN It is found in 1-56081-569-8).Although any method and material similar or equivalent with those described herein can be used for It tests in practice of the invention, but this document describes typical material and methods.When the present invention is described and claimed as, will make With following term.

It should also be understood that terms used herein are only used for the purpose of description particular aspects, limited without being intended to.

To understand scope of the present application, article " one (a) ", " one (an) ", " (the) " and " (said) " meaning Finger has one or more elements.

In addition, term " including (comprising) " as used herein and its derivative words, mean open-ended term, Feature, element, ingredient, group, integer and/or the step of specified statement, but be not precluded other unstated features, element, at Point, group, integer and/or step.Also apply the word with similar meaning above, such as term " including (including) ", " with (having) " and their derivative words.

It should be appreciated that be described as the certain components of "comprising" any aspect can also " by ... form " or " substantially By ... form ", wherein " by ... form " there is closed or restrictive sense and " substantially by ... form " means Including specified component but exclude other components, in addition to as substance existing for impurity, as the process for being used to provide for component Result and existing inevitable substance, and in order to achieve the purpose that add except the techniques described herein effect Component.For example, being covered using the composition that phrase " substantially by ... form " defines any of pharmaceutically acceptable Additive, excipient, diluent, carrier etc..In general, the composition being substantially grouped as by one group of group will be comprising less than 5% Weight ratio, the not specified component for being typically less than 3% weight ratio, more commonly less than 1% weight ratio.

It should be appreciated that can be limited by collateral condition or negative from claimed invention, clearly exclusion is fixed herein Justice is any component for being included.In addition, all ranges used herein include the endpoint of range, it further include the model of any centre It encloses a little, regardless of whether clearly indicating.

It is used herein such as " substantially ", " about ", " about " degree term mean the reasonable amount of modified term Error, so will not change to conspicuousness last result.These terms can be related to measurable magnitude, such as quantity, when away from Deng, it is intended that cover relative to ± the 20% of designated value or ± 10%, be more typically ± 5%, being even more typically from ± 1% and more logical It is often ± 0.1% variation, because the grade variations are suitable for carrying out disclosed method.

As used herein, " activation ", which is meant, is sufficiently stimulated with the immunocyte that induces detectable cell Proliferation State, the immunocyte such as CIK cell or T cell.Activation can also be generated and be can detect with the cell factor of induction Effector function it is related.Term " T cell of activation " refers in particular to carrying out fissional T cell.

It should also be understood that all base sizes given to nucleic acid or polypeptide or amino acid size, all molecular wts or The value of molecular mass is general, and is to provide for describing.Although can will be similar or equivalent with those described herein Method and material for the disclosure practice or test in, it is as follows described in suitable method and material.Abbreviation " such as (e.g.) " it is derived from Latin language exempli gratia, and herein for indicating non-limiting example.Therefore, abbreviation " such as (e.g.) " is synonymous with term " such as (for example) ".Word " or (or) " is intended to include " and (and) ", unless Context is otherwise explicitly indicated.

Term " antibody " is also referred to as " immunoglobulin " (Ig) in the art, is meant herein by pairs of weight The albumen of polypeptide chain and light polypeptide chain building；There are a variety of Ig isotypes, including IgA, IgD, IgE, IgG and IgM.When antibody just When really folding, every chain folding is connected at a variety of different globular domains, the globular domain by more linear polypeptide sequence It connects.For example, light chain immunoglobulin is folded into variable (V_L) structural domain and constant (C_L) structural domain, and heavy chain be folded into it is variable (V_H) structural domain and three constant (C_H、C_H2、C_H3) structural domain.Heavy chain and light variable domains (V_HAnd V_L) interaction lead Cause the formation of antigen binding domain (Fv).Each structural domain has the structure having determined familiar to those skilled in the art.

Light chain variable region and heavy chain variable region are responsible for combining target antigen, and therefore can show between antibody significant Sequence polymorphism.Constant region shows less sequence polymorphism, and is responsible for combining many native proteins important to cause Immune events.The antigen-binding determinants of molecule are contained in the variable region of antibody, and therefore determine antibody to the spy of its target antigen It is anisotropic.Most of sequence variabilities occur in six hypervariable regions, each variable heavy chain and light chain each three；Hypervariable region combine with Antigen binding site is formed, and helps to combine and identify antigenic determinant.Antibody is to the specificity and affinity of its antigen It is determined by size, shape and the chemical property of the structure of hypervariable region and surface that they are presented to antigen.In the presence of for reflecting The kinds of schemes in Ding Gao changeability area, those of two kinds most commonly Kabat schemes and the side those of Chothia and Lesk Case.Kabat et al. (1991a；The sequence variability of antigen binding domain 1991b) based on VH and VL structural domain defines " complementary Determine area " (CDR).Chothia and Lesk (1987) is based on V_HAnd V_LThe position of structure ring region defines " height change in structural domain Ring " (H or L).Due to these individual schema definitions are adjacent or overlapping CDR and hypervariable loop area, the skill of antibody art Art personnel usually interchangeably utilize term " CDR " and " hypervariable loop ", and they can be so used herein.Due to this A reason forms the region of antigen binding site, comprising the antibody of VH and VL structural domain, referred to as CDR L1, CDR L2,CDR L3,CDR H1,CDR H2,CDR H3；Or in the case where the antigen binding domain of heavy chain or light chain, claimed For CDR1, CDR2, CDR3.Herein according to the IMGT numbering system for being helped the comparison of variable domains by developing (Lefranc et al., 2003) refers to CDR/ ring.Within the system, conserved amino acid (such as Cys23, Trp41, Cys104, Phe/Trp 118 and the hydrophobic residue at position 89) always position having the same.Further it is provided that framework region (FR1: position 1 to 26；FR2:39 to 55；FR3:66 to 104；With FR4:118 to 128) and CDR (CDR1:27 to 38, CDR2: 56 to 65；It is defined with CDR3:105 to 117) standardized.

As mentioned in this article, " antibody fragment " may include any suitable antigen binding antibody piece known in the art Section.Antibody fragment can be naturally occurring antibody fragment, or can by operate naturally occurring antibody or by using Recombination method obtains.For example, antibody fragment can include but is not limited to Fv, scFv (scFv；By what is connected with peptide linker sequence VL and VH composition molecule), Fab, F (ab') 2, single domain antibody (sdAb；The segment being made of single VL or VH) and these In any multivalence present.Any antibody fragment is that those skilled in the art are understood in SEQ ID NO:2-30 Remain those of the bioactivity in conjunction with VEGFR-2 segment.

As used herein, term " synthetic antibody " means the antibody generated using recombinant DNA technology, such as by such as The antibody of phage expression as described herein.The term should also be interpreted to mean to produce by the DNA molecular of composite coding antibody The antibody of raw and DNA molecular expression antibody protein or the amino acid sequence of specified antibody, wherein using obtained by this field And it is well known that synthetic DNA or the technology of amino acid sequence obtain DNA or amino acid sequence.

In non-limiting example, antibody fragment can be the sdAb from naturally occurring source.Camelidae source Heavy chain antibody (Hamers-Casterman et al., 1993) lack light chain, and therefore their antigen binding site by one Referred to as V_HHStructural domain composition.It also observed sdAb, and referred to as VNAR (Nuttall et al., 2003) in shark.It can be with Based on people Ig heavy chain and sequence of light chain be engineered other sdAb (Jespers et al., 2004；To et al., 2005).Such as this paper institute With the V that, term " sdAb " includes by phage display or other technologies from any source_H、V_HH、V_LOr V_NARStorage cavern directly divides From those of sdAb recombinate the sdAb of generation from the sdAb of above-mentioned sdAb, and pass through humanization, affinity maturation, steady Fixedization, solubilising such as camelised or other antibody engineering methods those of further modify such sdAb and generate sdAb.This hair Homologue, derivative or the segment of bright the antigen binding function of also covering to retain sdAb and specificity.

SdAb is the excellent building module of novel antibody molecules, since it is with high thermal stability, high detergent resistance, right Relatively resistance (Dumoulin et al., 2002) and high yield (Arbabi-Ghahroudi et al., 1997) of protease；It can also With by from non-immune libraries separate (Li et al., 2009) or by external affinity maturation (Davies and Riechmann, 1996) it, is engineered with very high affinity.

Those skilled in the art by the structure of known single domain antibody (see, e.g., in Protein Data Bank 3DWT, 2P42).SdAb includes the single immunoglobulin domains for retaining immunoglobulin folding；Most notably, only three CDR forms antigen binding site.However and as understood by those skilled in the art, and not all CDR may be combination Needed for antigen.For example, but it not intended to be limiting, and the one, two or three in CDR can contribute to through the invention SdAb combine and identification antigen.SdAb or the CDR of variable domains are referred to herein as CDR1, CDR2 and CDR3, and such as Kabat et al. (1991b) defines number.

Epitope: antigenic determinant.Epitope is specific chemical group or peptide sequence on molecule, and the epitope is antigenicity , that is, cause special immune response.For example, antibody is in conjunction with specific antigen epitope specificity on polypeptide.Continuous ammonia Base acid makes discrete amino acid that can form epitope side by side by the three dimensional fold of albumen.It is commonly exposed to denaturing solvent It would generally lose when retaining and be derived from the formed epitope of continuous amino acid, and being handled with denaturing solvent and be formed by three dimensional fold Epitope.Epitope generally includes at least three kinds of, more frequent at least five kinds of, about 9 kinds or 8 to 10 kinds of ammonia in unique space conformation Base acid.The method for detecting the space conformation of epitope includes, such as X-ray crystallography and two dimensional NMR.For example, see “Epitope Mapping Protocols”Methods in Molecular Biology,Vol 66, Glenn E.Morris, Ed (1996) (" epitope mapping agreement " volume 66 in molecular biology method).In one embodiment, epitope In conjunction with such as MHC molecule of HLA molecule or DR molecule.These molecules with have by about 8 to about 10 amino acid it is all As 9 Amino acid scores every the polypeptides of correct anchor amino acids combine.

Term " antigen " or " Ag " as used herein are defined as causing the molecule of immune response.This immune response can It can relate to antibody generation or the activation of specificity immuning activity cell, or both.The skilled person will understand that any macromolecular packet It includes almost all of protein or peptide all can serve as antigen.In addition, antigen can be derived from recombination or genomic DNA.Technology people Member it will be understood that, comprising coding cause immune response albumen nucleotide sequence or partial nucleotide sequence any DNA therefore Encode " antigen " of term as used herein.Further, it will be understood by those skilled in the art that antigen does not need only by the complete of gene Longer nucleotide sequential coding.It is readily apparent that the present invention includes but is not limited to the partial nucleotide using more than one gene Sequence, and these nucleotide sequences are arranged with multiple combinations to cause desired immune response.In addition, technical staff will manage Solution antigen does not need to be encoded by " gene " at all.It is readily apparent that antigen can be synthesized or can be derived from biological sample.This Class biological sample can include but is not limited to tissue sample, tumor sample, cell or biofluid.

Term " anti-tumor effect " as used herein or " treatment of cancer " are meant can be by reducing gross tumor volume, reducing Tumour cell quantity reduces tumor growth rate, reduces transfer quantity, stable disease, increases life expectancy or improvement and cancer The relevant various physiological signs of the disease patient's condition are come the biological effect that proves." anti-tumor effect " can also be by as described herein Peptide, polynucleotides, cell and antibody prevent tumorigenic ability first to prove.

According to the present invention, term " self-antigen " means to be erroneously identified as external any itself resist by immune system It is former.Self-antigen including but not limited to cell protein, phosphoprotein, cell surface protein, cytolipin, nucleic acid, glycoprotein, including Cell surface receptor.

As used herein, term " self " means any material from same individual, will then be drawn again Enter the individual.

" allogeneic " means the graft of the different animals from same species.

" xenogenesis " means the graft from different plant species.

" homology is of the same race " means the graft from same individual.

As used herein, term " costimulation ligand " includes antigen presenting cell (for example, aAPC, dendritic cells, B cell Deng) on molecule, in T cell homologous costimulatory molecules specifically bind, to provide signal, the signal is in addition to by example Outside the main signal provided in conjunction with the MHC molecule for being loaded with peptide such as TCR/CD3 compound, mediate T cell response is gone back, including but not It is limited to proliferation, activation, differentiation etc..Costimulation ligand can include but is not limited to CD7, B7-1 (CD80), B7-2 (CD86), PD- L1, PD-L2,4-1BBL, OX40L, derivable costimulation ligand (ICOS-L), Intercellular Adhesion Molecule (ICAM), CD30L, CD40, CD70, CD83, HLA-G, MICA, MICB, HVEM, lymphotoxin-beta-receptor, 3/TR6, ILT3, ILT4, HVEM, combination The agonist or antibody of Toll ligand receptor and the ligand specifically bound with B7-H3.Costimulation ligand also especially cover with Be present in costimulatory molecules such as, but not limited to CD27, CD28 in T cell, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3 and with CD83 specificity knot The antibody of the specific binding of the ligand of conjunction.

" costimulatory molecules " mean the homologous binding partners in T cell, in conjunction with costimulation ligand specificity, thus Costimulation response is mediated by T cell, is such as, but not limited to proliferated.Costimulatory molecules include but is not limited to MHC I class molecule, BTLA and Toll ligand receptor.

As used herein, " costimulatory signal ", which means to combine with main signal such as TCR/CD3 connection, causes T cell to be proliferated And/or the signal of up-regulation or the downward of key molecule.

As used herein, " effective quantity " means to provide the amount for treating or preventing benefit.

" coding " refers to that specific nucleotide sequence such as gene, cDNA or mRNA are used as with determination in polynucleotides Other polymers are synthesized in the bioprocess of nucleotide sequence (for example, rRNA, tRNA and mRNA) or the amino acid sequence determined Intrinsic property and resulting biological property with the template of macromolecular.Therefore, if in cell or other biological system In, the transcription and translation of the mRNA corresponding to gene generates albumen, then gene coded protein.It can be by coding strand and noncoding strand Referred to as encode the albumen or other products of this gene or cDNA, the nucleotide sequence of the coding strand it is identical as mRNA sequence and It is usually provided in sequence table, the noncoding strand is used as the template that gene or cDNA are transcribed.

As used herein, " endogenic " mean from organism, cell, tissue or internal system or organism, cell, Any material that tissue or internal system generate.

As used herein, term " exogenous ", which is meant, introduces except organism, cell, tissue or system or in biology Any material generated except body, cell, tissue or system.

As used herein, term " expression " be defined as the specific nucleotide sequence driven by its promoter transcription and/ Or translation.

" expression vector " means that the carrier comprising recombination of polynucleotide, the recombination of polynucleotide include and core to be expressed The expression control sequence that nucleotide sequence is operably connected.Expression vector includes enough cis-acting elements for expression； Other elements for expression can be provided by host cell or in vitro in expression system.Expression vector includes that incorporation recombination is more The all that expression vector known in the art of nucleotide, such as clay, plasmid (such as it is exposed or be comprised in liposome In) and it is viral (such as slow virus, retrovirus, adenovirus and adeno-associated virus).

" homologous " means the sequence similarity or sequence identity between two polypeptides or between two nucleic acid molecules.When Two positions compared in sequence are occupied by identical base or amino acid monomer subunit, for example, if in two DNA moleculars When position in each is occupied by adenine, then molecule is homologous at this position.Homology between two sequences Percentage be the shared matching of two sequences or homologous position quantity divided by the positional number compared multiplied by 100 function.For example, If 6 in two sequences in 10 positions be it is matched or homologous, this two sequences is 60% homologous.Citing For, DNA sequence dna ATTGCC and TATGGC share 50% homology.In general, when comparing two sequences, be compared with Provide maximum homology.

" separation " means to change from native state or remove.For example, the nucleic acid or peptide that are naturally present in live animal are not It is " separation ", but the identical nucleic acid or peptide that are partially or wholly separated from the coexisting materials of its native state are " separation ". Isolated nucleic acid or albumen can exist in the form substantially purified, or can reside in non-natural environment such as such as host In cell.

In the context of the present invention, using the abbreviation of following common nucleic acid base." A " means that adenosine, " C " mean that born of the same parents are phonetic Pyridine, " G " mean that guanosine, " T " mean that thymidine and " U " mean uridine.

Unless otherwise stated, " nucleotide sequence of encoding amino acid sequence " includes for degeneracy form and coding each other All nucleotide sequences of same amino acid sequence.The phrase nucleotide sequence for encoding albumen or RNA can also be to a certain degree Upper includes introne, and the nucleotides sequence for encoding albumen, which is listed in certain forms, can contain introne.

As used herein, " slow virus " means a category of Retroviridae (Retroviridae).Slow virus is inverse It is unique in terms of it can infect non-dividing cell in Retroviral；It is thin that a large amount of hereditary information can be delivered to host by them In the DNA of born of the same parents, therefore they are one of most effectual ways of gene delivery vector.HIV, SIV and FIV are the realities of slow virus Example.The means for realizing the gene transfer of the level of signifiance in vivo are provided derived from the carrier of slow virus.

" transposons " or " can transposable element " be to can change its position in genome, is generated sometimes or reversal mutations And change the DNA sequence dna of cellular genome size.Swivel base frequently results in the duplication of transposons.There are two distinct types of swivel bases Son: II class transposons, it from the DNA that a place is moved to another place by directly forming；It is inverse with I class transposons Transposons is transcribed, DNA is transcribed into RNA first by it, prepares the DNA copy of RNA using reverse transcriptase then to be inserted into new position It sets.Swivel base enzyme interacting of the transposons usually with mediation transposons movement.Transposons/transposase system non-limiting example Including sleeping beauty, Piggybac, The Frog Prince (Frog Prince) and prince charming (Prince Charming).

As used herein, term " adjusting " means there is no treatment or compound, with the response in individual Level compare and/or with it is identical in other aspects, but response level is compared in the individual of untreated, mediates response water in individual It is flat detectable to increase or decrease.The term covers upset and/or influences natural signals or response, to be usually in individual Beneficial therapeutic response is mediated in people.

Term " being operably connected " means the functional connection between regulating and controlling sequence and heterologous nucleic acid sequence, leads to the latter Expression.For example, when the first nucleic acid sequence and second nucleotide sequence are in functional relationship, by the first nucleic acid sequence and the second core Acid sequence is operably connected.For example, if promoter influences the transcription or expression of coded sequence, by promoter and code sequence Column are operably connected.In general, the DNA sequence dna being operably connected is continuous, and if necessary in identical reading frame Two protein-coding regions of middle connection.

" overexpression " of term " overexpression " tumour antigen or tumour antigen is intended to indicate that relative to coming self-organizing or device Expression in the normal cell of official, the cell of specific organization or intraorganic solid tumor from disease area such as patient The aberrant expression level of middle tumour antigen.It can determine to have by standard test known in the art and table is crossed with tumour antigen Up to the patient of the solid tumor or hematologic malignancies that are characterized.

" parenteral " of immunogenic composition is given including for example subcutaneous (s.c.), intravenous (i.v.), intramuscular (i.m.) or breastbone inner injection or infusion techniques.

As used herein, term " polynucleotides " is defined as nucleotide chain.In addition, nucleic acid is the polymer of nucleotide. Therefore, nucleic acid and polynucleotides as used herein are interchangeable.The generally known nucleic acid of those skilled in the art is multicore glycosides Acid can be hydrolyzed into monomer " nucleotide ".Monomeric nucleotide can be hydrolyzed into nucleosides.As used herein, multicore glycosides Acid includes but is not limited to all nucleic acid sequences that any means obtain as obtained by this field, including but not limited to recombination hand Section (uses common clone technology and PCR etc. from recombination library or cellular genome cloning nucleic acid sequences), and passes through synthesis hand Section.

As used herein, term " peptide ", " polypeptide " and " albumen " is used interchangeably, and is referred to by being connected by covalent peptide bonds The compound of the amino acid residue composition connect.Albumen or peptide must contain at least two amino acid, and to may include albumen There is no limit for the maximum quantity of the amino acid of sequence or peptide sequence.Polypeptide includes being connected to each other by peptide bond comprising two or more Any peptide or protein of multiple amino acid.As used herein, which refers to short chain, is also generally referred to as example in the art Such as peptide, oligopeptides and oligomer, and refer to longer chain, be usually referred in the art as albumen, there are many kinds of types. " polypeptide " includes, for example, bioactive fragment, substantially homologous polypeptide, oligopeptides, homodimer, heterodimer, polypeptide variant, Modified polypeptide, derivative, analog, fusion protein etc..Polypeptide includes native peptides, recombinant peptide, synthetic peptide or combinations thereof.

As used herein, term " promoter " is defined as needed for starting polynucleotide sequence specific transcriptional, by thin Born of the same parents' synthesis machine or the DNA sequence dna of the synthesis machine of introducing identification.

As used herein, term " promoter/regulating and controlling sequence " means the base being operably connected with promoter/regulating and controlling sequence Because of nucleic acid sequence needed for product expression.In some cases, which can be core promoter sequence, and in other feelings Under condition, which can also include other controlling elements needed for enhancer sequence and gene product expression.Promoter/regulation sequence Column can be, for example, with promoter/regulating and controlling sequence of tissue specific way expressing gene product.

" composing type " promoter is such nucleotide sequence: when the polynucleotides of itself and coding or specified gene product can When being operatively connected, gene product is caused to generate in cell under most of or all physiological conditions of cell.

" induction type " promoter is such nucleotide sequence: when the polynucleotides of itself and coding or specified gene product can When being operatively connected, substantially only just cause gene product thin when the inducer for corresponding to promoter is present in cell It is generated in born of the same parents.

" tissue specificity " promoter is such nucleotide sequence: when itself and encoding gene or the multicore specified by gene When thuja acid is operably connected, substantially only the cell of the cell organization type that corresponds to promoter when just gene is caused to produce Object generates in cell.

Such as mean to identify specific antigen but substantially nonrecognition herein in regard to the term " specific binding " that antibody uses Or combine the antibody of other molecules in sample.For example, antibody in conjunction with the antigentic specificity from a kind of species can also be with With the antigen binding from one or more species.But such cross species reactivity itself can't be by the classification of antibody Change into specificity.In another example, the antibody in conjunction with antigentic specificity can also be with the not iso-allele shape of antigen Formula combines.However, the classification of antibody can't be changed into specificity by such cross reactivity itself.In some cases, may be used To be used for term " specific binding " or " specifically combining " to refer to the phase interaction of antibody, albumen or peptide with the second chemical species With to mean that interaction depends on the presence of special construction (e.g., antigenic determinant or epitope) on chemical species；For example, Antibody is the generally recognized and is bound to specific protein structure rather than albumen.If antibody is that specificity is directed to epitope " A ", Molecule (or free, unlabelled A) containing epitope A is will reduction containing the presence in markd " A " and the reaction of antibody The amount of the A of label in conjunction with antibody.

Term " epitope " means can be with the protein determinant in conjunction with antibody specificity.Epitope is usually living by the chemistry of molecule Property surface group such as amino acid or carbohydrate side chain composition, and usually have specific three-dimensional structure characteristic and specific charge special Property.The difference of conformation and non-conformational epitope is, in the presence of denaturing solvent, lose with the former and and non-the latter combination.

Term " stimulation " means through the zygotic induction of stimulation molecule (such as TCR/CD3 compound) and its cognate ligand Primary response, thus mediated signal transduction event, such as, but not limited to via the signal transduction of TCR/CD3 complex.Stimulation can To mediate the expression of the change of certain molecules, TGF-β is lowered and/or cytoskeletal structure recombinates etc..

As used herein, term " stimulation molecule " means the molecule in T cell, with antigen presenting cell present on it is same Source stimulates ligand specificity to combine.

As used herein, " stimulation ligand " means such ligand: when its be present in antigen presenting cell (for example, aAPC, Dendritic cells, B cell etc.) on when, can be with the homologous binding partners (referred to herein as " stimulation molecule ") in T cell Specific binding, so that primary response is mediated by T cell, including but not limited to activate, start immune response, proliferation etc..Stimulation Property ligand be well-known in the art, and it is anti-especially to cover the MHC I class molecule, anti-cd 3 antibodies, super-agonists for being loaded with peptide CD28 antibody and the anti-CD2 antibody of super-agonists.

As used herein, " substantially purifying " cell is cell substantially without other cell types.Substantially purify Cell also refer to from the cell separated to other relevant cell types usual under its naturally occurring state.In certain feelings Under condition, the cell mass substantially purified refers to homologous cell mass.In other cases, the term only refer to from at them Native state under natural relevant cell separation cell.In some terms, cultivating cell in vitro.Other aspects, not in body Outer culture cell.

As used herein, " treatment " or " therapy " is the method for obtaining beneficial or desired clinical effectiveness.For herein The purpose, beneficial or desired clinical effectiveness include but is not limited to mitigate symptom, mitigate disease degree, stabilization (i.e. not Deteriorate) morbid state, delay or slow the progress of the disease, improve or ease the disease state and alleviate (either partially or it is complete Portion), it is either detectable or undetectable.If not receiving treatment or therapy, " treatment " and " therapy " can also anticipate Taste with it is expected survival compared to extend survive.Therefore, " treatment " or " therapy " is intended to the pathology for changing illness and carries out Intervene.Specifically, the pathology of disease or illness (such as cancer) can directly be prevented, slow down or otherwise be reduced to treatment or therapy, Or cell can be made more susceptible to the treatment or therapy that pass through other therapeutic agents.

Term " therapeutically effective amount ", " effective quantity ", " sufficient amount " mean to work as and give to the object including mammal for example It is enough the quantity to achieve desired results, such as the quantity of effective treating cancer when people.The effective quantity of compound as described herein Changed according to the factor of the weight of such as morbid state, age, gender and object.As it will be appreciated by the skilled person that can be with Dosage or therapeutic scheme are adjusted to provide optimal therapeutic response.For example, in some aspects, giving the anti-of therapeutically effective amount VEGFR-2 sdAb is enough to reduce, inhibit or prevent the formation of blood vessel relevant to tumour progression or transfer.

In addition, the therapeutic scheme of the object with therapeutically effective amount can be made of single give, or alternatively wrap Include a series of applications.The length for the treatment of phase depends on many factors, such as age of the severity of disease, object, reagent Concentration, patient are to the responsiveness or their combination of reagent.It should also be understood that the effective dose of the reagent for treatment can be in spy It is increased or decreased during different therapeutic scheme.The variation of available dosage is measured simultaneously by standard diagnostics known in the art And it becomes apparent.It in some aspects, can be in the routine treatment with disease or illness (such as cancer) for being discussed Antibody as described herein is given before, during or after treatment.

As used herein, term " transfection " or " conversion " or " transduction " mean and are shifted Exogenous Nucleic Acid by it Or introduce the process of host cell." transfection " or " conversion " or " transduction " cell be with Exogenous Nucleic Acid transfection, The cell of conversion or transduction.Cell includes main theme cell and its filial generation.

As used herein, phrase " under transcription control " or " being operably connected " mean promoter relative to polynucleotides In correct position and direction, to control the expression of transcripting starting and polynucleotides by RNA polymerase.

" carrier " is composition of matter, and it includes isolated nucleic acid and the delivery of nucleic acids that can be used to separate is to thin Portion intracellular.Many carriers be it is known in the art, including but not limited to linear polynucleotides, with ion or amphiphilic compound phase Polynucleotides, plasmid and the virus of pass.Therefore, term " carrier " includes the plasmid independently replicated or virus.The term should also be by Be construed to include that nucleic acid is promoted to be transferred to non-plasmid and non-viral compound in cell, such as polylysin compounds, Liposome etc..The example of viral vectors includes but is not limited to adenovirus vector, gland relevant viral vector, retroviral vector Deng.

Term " patient ", " individual (subject) ", " individual (individual) " etc. can be used interchangeably herein, And refer to any animal for being suitable for method described herein or its cell, it is either external or in situ.

In addition, term " patient ", " individual (subject) " and " individual (individual) " are included therein and can trigger The living organism (such as mammal) of immune response.At certain non-limiting aspects, patient, object or individual are mammals And including people, dog, cat, mouse, rat and their genetically modified organism.The term as used herein " object " refers to the animal kingdom Any member, typically refer to mammal.Term " mammal " means any animal for being classified as mammal, including The mankind, other High Primates, domestic animal and zoo, movement can animal or pet, such as dog, cat, ox, horse, sheep, pig, Goat, rabbit etc..In general, mammal refers to the mankind.

It gives and is given including (concurrent) simultaneously and continuous with random order with one or more other therapeutic agents " combination " It gives.

Term " pharmaceutically acceptable " means remaining composition portion of the preparation of compound or compound combination and medicinal usage Split-phase is held, and generally according to set government standard (including those of promulgating standard from United States Food and Drag Administration) to It is safe that the mankind, which give,.

Term " pharmaceutically acceptable carrier " includes but is not limited to solvent, decentralized medium, coating, antibacterial agent, antimycotic Agent, isotonic agent and/or absorption delaying agent etc..The use of pharmaceutically acceptable carrier is well-known.

Separation: " separation " biological components (such as protein) are substantially from the naturally occurring life of component wherein In object cell other biological ingredient (i.e. chromosome and exchromosomal DNA and RNA, other albumen and organelle) separation or Purifying.It include the albumen and peptide purified by standard purification methods by the albumen of " separation " and peptide.The term further includes By the albumen and peptide and chemically synthesized albumen and peptide that recombinantly express preparation in host cell.

As used herein, " tumour " means the cell growth and proliferation of all superfluous lifes, and either pernicious is still benign And before all cancers and cancerous cells and tissue.

Term " cancer " and " carcinous " mean or describe usually to be grown to spy in mammal with not modulated cell The physiological status of sign.As used herein, cancer or carcinous it is defined as with abnormal cell rapidly and uncontrolled growth The disease being characterized.Cancer cell local propagation or can travel to other portions of body by hematological system and lymphatic system Position.The example of various cancers includes but is not limited to breast cancer, prostate cancer, oophoroma, cervical carcinoma, cutaneum carcinoma, cancer of pancreas, colon The carcinoma of the rectum, kidney, liver cancer, the cancer of the brain, lymthoma, leukaemia, lung cancer etc..

Cancer to be treated can be any kind of malignant tumour, and on one side, be lung cancer include cellule lung Cancer and non-small cell lung cancer (such as gland cancer), cancer of pancreas, colon cancer (such as colorectal cancer, such as adenocarcinoma of colon and colon Adenoma), the cancer of the esophagus, oral squamous cell carcinomas, tongue cancer, gastric cancer, liver cancer, nasopharyngeal carcinoma, lymphoid hematopoetic tumor (such as acute lymphoblastic is thin Born of the same parents' property leukaemia, B cell lymphoma, Burkitt's lymphoma), non Hodgkin lymphom (such as lymphoma mantle cell), suddenly It is odd king's evil, myelomatosis (such as acute myelogenous leukemia (AML) or chronic myelogenous leukemia (CML)), acute Lymphoblastic leukemia, chronic lymphocytic leukemia (CLL), follicular carcinoma of thyroid, myeloproliferative disorder are comprehensive Sign (MDS), the tumour in mesenchyma source, soft tissue sarcoma, embryonal-cell lipoma, Gastrointestinal Stromal sarcoma, pernicious peripheral nerve sheath are swollen It is tumor (MPNST), Ewing sarcoma, leiomyosarcoma, mesenchyma chondrosarcoma, lymphosarcoma, fibrosarcoma, rhabdomyosarcoma, black Plain tumor, teratocarcinoma, neuroblastoma, brain tumor, medulloblastoma, glioma, benign skin tumour (such as angle Change acanthoma (acanthomata)), breast cancer (such as advanced breast cancer), kidney, nephroblastoma, oophoroma, cervical carcinoma, carcinoma of endometrium, wing Guang cancer, prostate cancer (including terminal illness and hormone-refractory prostate cancer), carcinoma of testis, osteosarcoma, head and neck cancer, epidermal carcinoma, Huppert's disease (such as Refractory Multiple Myeloma) or celiothelioma.On the one hand, cancer cell is derived from solid tumor.Typically, Cancer cell is derived from breast cancer, colorectal cancer, melanoma, oophoroma, cancer of pancreas, gastric cancer, lung cancer or prostate cancer.More typically, Cancer cell is derived from prostate cancer, lung cancer, breast cancer or melanoma.

" chemotherapeutant " is the chemical compound for treating cancer.The example of chemotherapeutant includes alkylating agent, all Such as thiotepa, CYTOXAN^TMCyclophosphamide；Alkyl sulfonates, such as busulfan, Improsulfan and piposulfan；Azacyclo- third Alkanes, such as Benzodepa (benzodopa), carboquone, meturedepa (meturedopa) and uredepa (uredopa)； The aziridine type and methylamelamines (methylamelamines), including hemel, triethylenemelamine, triethylphosphoramide (trietylenephosphoramide), triethylene thiophosphamide (triethiylenethiophosphoramide) and Trimethylolmelamine (trimethylolomelamine)；Acetic acid original compound (acetogenins), such as bullatacin (bullatacin) and Bradley its octanone (bullatacinone)；Camptothecin, such as topotecan；Bryostatin； callystatin；CC-1065 and its Adozelesin, Carzelesin and Bizelesin synthetic analogues；Cryptophycins (cryptophycins), such as cryptophycin 1 and cryptophycin 8；Its spit of fland (dolastatin) of Duola department；Duocarmycins, it is all Such as synthetic analogues KW-2189 and CB1-TM1；The Lip river Ai Zhisai element (eleutherobin)；Water ghost any of several broadleaf plants alkali； sarcodictyins；Sponge inhibin；Nitrogen mustards, such as Chlorambucil, Chlornaphazine, cholophosphamide (cholophosphamide), Estramustine, ifosfamide, mechlorethamine, mustron (mechlorethamine oxide hydrochloride), melphalan, novembichin, phenesterin, prednimustine, Trofosfamide, uracil mustard；Nitroso ureas, such as Carmustine, chloramphenicol, Fotemustine, lomustine, Nimustine And Ranimustine；Antibiotics, such as enediyne antibiotics, such as calicheamicin (calicheamicin), especially Katy are mould Plain γ 1I and calicheamycin ω I1, up to endomycin (including reaching endomycin A), diphosphonates such as clodronate, Ai Sibo is mould Element, neoearcinostain chromophore and related chromoprotein enediyne antibiotic chromophore；Aclacinomycin；D actinomycin D；Pacify aspergillus Element；Azaserine；Bleomycin；Act-C (cactinomycin)；Carubicin (carabicin)；Carminomycin； Carzinophillin；Chromomycin；Actinomycin D (dactinomycin)；Daunomycin；Detorubicin；6- diazonium -5- oxo-L- is just Leucine；ADRIAMYCIN^TMDoxorubicin, including morpholino-Doxorubicin, Cyanomorpholino-Doxorubicin, 2- pyrrolin And-Doxorubicin and deoxydoxorubicin；Epirubicin；Esorubicin；Idarubicin；Marcellomycin；Mitomycin, it is all As mitomycin C, mycophenolic acid, nogalamycin, olivomycin class, Peplomycin, porfiromycin, puromycin, triferricdoxorubicin, Rodorubicin, streptonigrin, streptozotocin, tubercidin, ubenimex, Zinostatin and zorubicin；Antimetabolite, it is all Such as methotrexate and 5 FU 5 fluorouracil (5-FU)；Folacin, such as denopterin, amethopterin, pteropterin, front three are bent It is husky；Purine analogue, such as fludarabine, Ismipur, thiapurine and thioguanine；Pyrimidine analogue, such as Anxi He urinates shore, azacitidine, 6- aza uridine, Carmofur, cytarabine, di-deoxyuridine, doxifluridine, enocitabine and fluorine Glycosides；Androgens, such as calusterone, dromostanolone propionate, epithioandrostanol, Mepitiostane and Testolactone；Antiadrenergic drug, such as Aminoglutethimide, mitotane and Trilostane；Folic acid supplement, such as folinic acid；Aceglatone；Aldophosphamideglycoside；Amino Levulic acid；Eniluracil；Amsacrine；bestrabucil；Bisantrene；Edatrexate；Defosfamide (defofamine)；Ground Mei Kexin；Diaziquone；Eflornithine (elfornithine)；Elliptinium Acetate；Epothilones；Ethoglucid；Gallium nitrate；Hydroxyl Urea；Lentinan；Lonidamine；CHROMATOGRAPHIC FRACTIONATION AND MASS, such as Mei Dengxin and ansamitocin；Mitoguazone；Mitoxantrone；Piperazine does not reach Alcohol；Nitracrine (nitraerine)；Pentostatin；Benzene carrys out beautiful spy；Pirarubicin；Losoxantrone；Podophyllic acid；2- ethyl acyl Hydrazine；Procarbazine；PSKTM polysaccharide compound；Razoxane；Rhizomycin；Sizofiran；Spirogermanium；Tenuazonic acid；Three Quinone imine；2,2', 2 "-trichlorotriethylamines；Trichothecenes, such as T-2 toxin, myconomycin A, myrothecin A And anguidin；Urethane；Eldisine；Dacarbazine；Mannomustin；Dibromannitol；Mitolactol；Piperazine moors bromine Alkane；gacytosine；Arabinoside (" Ara-C ")；Taxanes, such as TAXOL^TMTaxol, ABRAXANE^TMTaxol Albumin without cremophor be engineered nanoparticle formulations, TAXOTERE^TMAnd docetaxel；Chlorambucil； GEMZAR^TMGemcitabine；6- thioguanine；Purinethol；Amethopterin；Platinum coordination complex, such as cis-platinum, oxaliplatin and Carboplatin；Vinblastine；Platinum；Etoposide (VP-16)；Ifosfamide；Vincristine；NAVELBINE^TMVinorelbine；Promise disappears Spirit；Teniposide；Edatrexate；Daunomycin；Aminopterin；Xeloda；Ibandronate；Irinotecan, such as CPT11； Topoisomerase enzyme inhibitor, such as RFS 2000；Difluoromethylornithine (DMFO)；Retinoid, such as retinoic acid；Card Train his shore；With any of the above-described kind of pharmaceutically acceptable salt, acid or derivative.

This definition further include for regulating and controlling or inhibitory hormone is to the antihormone agent of the effect of tumour, such as anti-estrogens and Selective estrogen receptor modulators (SERMs), including such as tamoxifen (including NOLVADEX^TMTamoxifen), Lei Luoxi Sweet smell, Droloxifene, 4- hydroxyl tamoxifen, Trioxifene, keoxifene, LY117018, Onapristone and FARESTON support are auspicious Meter Fen；Inhibit the aromatase inhibitor (its estrogen regulated and controled in adrenal gland generates) of enzyme aromatase enzyme, such as 4 (5)-imidazoles Class, aminoglutethimide, MEGASE^TMMegestrol acetate, AROMASIN^TMExemestane, Formestane, Fadrozole, RIVISOR^TM Vorozole, FEMARA^TMLetrozole and ARIMIDEX^TMAnastrozole；And anti-androgens, such as Flutamide, Nilutamide, Bicalutamide, Leuprorelin and Goserelin；And troxacitabine (bis- furfuran alkane nucleosides analogue of cytosine of 1,3-)；Antisense Oligonucleotides especially inhibits to participate in those of gene expression in the signal transduction pathway of abnormal cell proliferation, such as, PKC- α, Ralf and H-Ras；Ribozyme, such as vegf expression inhibitor is (for example, ANGIOZYME^TMRibozyme) and HER2 expression Inhibitor；Antibody, such as anti-VEGF antibody are (for example, AVASTIN^TMAntibody)；Vaccine, such as gene therapy vaccine, such as ALLOVECTIN^TMVaccine, LEUVECTIN^TMVaccine and VAXID^TMVaccine；PROLEUKIN^TMrIL-2；LURTOTECAN^TMIt opens up Flutter 1 inhibitor of isomerase；ABARELIX^TMrmRH；With any of the above-described kind of pharmaceutically acceptable salt, acid or derivative.

In some terms, antibody as described herein is added or acts synergistically with other standard anti-cancer regimens.

" variant " be biologically active antibody or its have it is different from the sequence of anti-VEGFR-2 sdAb (by means of may compare Sequence in insertion, delete, modification and/or replace one or more amino acid residues) amino acid sequence segment, such as Those of statement in SEQ ID NO:2-53.Variant usually has with comparable sequence less than 100% sequence identity.So And generally, biologically active variant know from experience have with comparable sequence at least about 70% amino acid sequence identity, such as at least About 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% Sequence identity.Variant includes the peptide fragment for retaining at least ten amino acid of VEGFR-2 binding ability.Variant also includes wherein One or more amino acid residues are added to the polypeptide in N-terminal or C-terminal or comparable sequence.Such as at N-terminal " MQV " can be replaced by " MKKQV " and still retain the binding ability with VEGFR-2.Variant also includes many amino Sour residue is deleted or by the optionally substituted polypeptide of one or more amino acid residues.Can also covalently modification variant, example Such as replaced by the part different from naturally occurring amino acid or non-naturally occurring to generate by modified amino acid residue Amino acid.

As defined herein, " percent amino acid identity " is to introduce notch in aligned sequences and if necessary to obtain After maximum Percentage of sequence identity (and not considering a part of any conservative substitution as sequence identity), candidate sequence The homogeneity percentage of column and the amino acid residue in interested sequence (polypeptide such as of the invention).There is no N-terminal, the end C End or internal extended, the deletion or insertion of candidate sequence shall not be construed to influence sequence identity or homology.For than Pair method and computer program be well known in the art, such as " BLAST ".

For the purposes herein, " active " or " activity " means the biological activity of sdAbs as described herein and/or exempts from Epidemic disease activity, wherein " biology " activity refers to biological function caused by sdAbs (or inhibit or stimulation).

Therefore, mean to open up when " biological activity " or " bioactivity " is used in conjunction with " -2 sdAbs of anti-VEGFR " Show or share VEGFR-2 antibody effector function -2 sdAbs of anti-VEGFR or its segment.The bioactivity of such antibody First is that it at least partly inhibits the ability of vascularization.

Term " inhibition " or " inhibition " mean the function or activity for reducing, limiting, blocking or neutralize VEGFR-2.These Term include VEGFR-2 function or it is active it is complete inhibition or partial inhibition.

" -2 single domain antibody of anti-VEGFR " includes remaining the of the invention of VEGFR-2 specificity to resist as used herein The modification of VEGFR-2 antibody.Such modification includes but is not limited to and such as chemotherapeutant (such as cis-platinum, taxol, Ah mould Element) or cytotoxin (such as albumen or non-protein organic chemistry therapeutic agent) effector molecule engagement.Modification further include but It is not limited to engage with detectable report section.The modification for extending antibody half life (such as Pegylation) is also included within It is interior.Albumen and non-protein preparation can be engaged with antibody by method as known in the art.Joint method includes direct It connects, via the connection of covalently adhesive joint and the specific bond of a pair of of member's (such as Avidin-biotin).This Class method includes such as Greenfield etc., Cancer Research 50, adriamycin described in 6600-6607 (1990) Engagement (being incorporated herein by reference) and Amon etc., Adv.Exp.Med.Biol.303,79-90 (1991) and Kiseleva etc., MoI.Biol. (USSR) 25,508-514 (1991) it is described those, all by reference by the two It is incorporated herein.

Antibody of the invention or its segment are VEGFR-2 specificity, the VEGFR-2 many solid tumors such as but not It is raised for being limited to the expression in breast cancer, cancer of pancreas, oophoroma, lung cancer and colon cancer.

Sequence (also known as KDR D1-7, sKDR D1-7, the Kinase insert Domain receptor, Protein-Tyrosine of VEGFR-2 Kinases receptors Flk-1, CD309, type III receptor tyrosine kinase, FLK1) sequence of SEQ ID NO:1 can be but not limited to Column:

Range: running through the disclosure, various aspects described herein can be presented with range format.It should be appreciated that range format Description just for the sake of convenienct and succinct, and be not construed as the unmodifiable limitation to range described herein. It is intended, therefore, that the description of range specifically discloses all possible subrange and the single number within the scope of this.For example, It is believed that specifically disclose subrange to the description of such as 1 to 6 range, such as 1 to 3,1 to 4,1 to 5,2 to 4,2 to 6, 3 to 6 etc., and individual digit in the range, such as 1,2,2.7,3,4,5,5.3 and 6.Range regardless of range, This is all suitable for.

Many patent applications, patent and publication has been mentioned above to help to understand the aspect.These bibliography In each piece be integrally incorporated by reference herein.

The present invention relates to the composition and method for treating cancer, more certain aspects are the solid tumor of VEGF expression R-2. The present invention relates to the adoptive transcellular strategies that the immunocyte of Chimeric antigen receptor (CAR) is expressed through transduceing.CAR is It will be based on the T cell of the antibody and activating cell intracellular domain to desired antigen (for example, tumour antigen) with specificity Receptor combination is to generate the molecule of the chimeric protein with specificity antineoplastic Cell-mediated Immunity.The T cell of gene modification is treated Method includes that the nucleic acid of encoding chimeric antigen receptor (CAR) is introduced to T cell, and the thus obtained T for introducing gene of isolated growth is thin Born of the same parents, then by cell infusion to patient, wherein CAR with specificity and has activation T thin the surface antigen of tumour cell The ability of born of the same parents.

The present invention relates generally to the purposes of the T cells such as this, the T cell is through gene modification to stablize expression to expression The solid tumor of VEGFR-2, its segment and/or its epitope have the CAR of specificity.The T cell of expression CAR is referred to herein as CAR-T cell or the T cell of CAR modification.T cell is carried out gene modification and expresses CAR to stablize by certain aspects of the invention, The CAR by the antigen recognizing structural domain of the sdAb of VEGFR-2 specificity and one or more intracellular costimulation structural domains with And signal domain is combined into single chimeric protein.

Chimeric antigen receptor (CAR)

CAR of the invention has (is also known as kinases knot for vascular endothelial growth factor receptor -2 (VEGFR-2) in people The area Gou Yu (KDR) and the specificity that Fetal liver kinase-1 (Flk-1) is also known as in mouse.VEGFR-2 is vascular endothelial growth factor The receptor of sub (VEGF) has 7 extracellular domains, and by vascular endothelial cell selective expression.It swells in tumor vessel Tumor endothelial cell is overexpressed VEGFR-2.In addition, normal cell, non-tumor cell or non-cancerous cell being capable of VEGF expression R- 2.However, in such cases, the VEGFR-2 expression of normal cell, non-tumor cell or non-cancerous cell is thin not as good as tumour The expression of born of the same parents or cancer cell is steady.In this regard, with the VEGFR- of normal cell, non-tumor cell or non-cancerous cell 2 expression are compared, and tumour cell or cancer cell can be overexpressed VEGFR-2 or with higher horizontal expression VEGFR-2 significantly. VEGFR-2 enhances Tumor angiogenesis, growth and transfer.It is without being held to a particular theory, it is believed that by combining VEGFR- 2, CAR-T target and destroy the endothelial cell of VEGF expression R-2 in tumor vessel, attack tumor vessel, reduce or eliminate swollen Tumor promotes infiltration of the immunocyte to tumor locus, and enhances/expand antitumor response.

The tumour theory of anti-angiogenesis provides many advantages.For example, because endothelial cell is that gene is stable, it is believed that Drug resistance is impossible.In addition, blood flow makes it easy to close to blood vessel endothelium, and believe side effect and the poison of normal tissue Property is limited.Moreover, it is believed that being the tumor vascular death for destroying and accelerating tumour cell.Also believe it is the interior of generation blood vessel Chrotoplast equably raises antigen, such as VEGFR-2 expression.Moreover, the tumor therapy of anti-angiogenesis can be applied to include blood The solid tumor of pipe supply.

On the one hand, this document describes the CARs of engineering.

In a specific non-limiting example, CAR as described herein includes single domain anti-VEGFR-2 antibody, the single domain Anti-VEGFR-2 antibody may include that any following sequence (it should be noted that other than their SEQ ID NO, also passes through them Inside name come defined nucleotide sequence, such as AB1, V21 etc..These names are interchangeably used herein, however, identifying if There are any problems for sequence, then being considered as SEQ ID NO is most important definition).

SEQ ID NO:2-AB1；V21；It is underlined in CDR

SEQ ID NO:3-V21H1；The residue of runic is the estimated position for adhering to urase

SEQ ID NO:4Have the AB1 of joint sequence；V21H2

SEQ ID NO:5Have the AB1m-2 of joint sequence；V21H3

SEQ ID NO:6-AB1C；V21H4

SEQ ID NO:7Have the AB1 of joint sequence 2；VR2-21

SEQ ID NO:8-AB1m

SEQ ID NO:9Have the AB1m of joint sequence；V21N2K

SEQ ID NO:10-AB1m-2

SEQ ID NO:11-AB2；V18

SEQ ID NO:12Have the AB2 of joint sequence

SEQ ID NO:13Have the AB2 of joint sequence 2；VR2-801-18

SEQ ID NO:14-V18H3

SEQ ID NO:15-AB2m

SEQ ID NO:16Have the AB2m of joint sequence

SEQ ID NO:17-AB2m-2

SEQ ID NO:18Have the AB2m-2 of joint sequence；V18H2

SEQ ID NO:19-AB3；V45

SEQ ID NO:20Have the AB3 of joint sequence；V45H1

SEQ ID NO:21Have the AB3 of joint sequence 2；VR2-801-45

SEQ ID NO:22-AB3m

SEQ ID NO:23Have the AB3m of joint sequence；V45N2K

SEQ ID NO:24-V45H2

SEQ ID NO:25-AB4；V38

SEQ ID NO:26Have the AB4 of joint sequence

SEQ ID NO:27Have the AB4 of connector 2；VR2-38

SEQ ID NO:28-AB4m

SEQ ID NO:29Have the AB4m of joint sequence

SEQ ID NO:30-AB4c；V38H3

Or with its have at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, the sequence of at least 92%, at least 93%, at least 94% or at least 95% identity, or the sequence substantially same with it.

These sequences can be encoded by any nucleic acid sequence for obtaining the amino acid sequence, it should be understood that attribution In the degeneracy of genetic code.The example that the nucleic acid sequence of above-described amino acid sequence can be encoded includes but is not limited to:

SEQ ID NO:31-AB1；V21

SEQ ID NO:32-AB1

SEQ ID NO:33Have the AB1 of joint sequence；V21H2

SEQ ID NO:34Have the AB1 of joint sequence 2；VR2-21

SEQ ID NO:35-AB1c；V21H4

SEQ ID NO:36-AB1m-2

SEQ ID NO:37Have the AB1m-2 of joint sequence；V21H3

SEQ ID NO:38-AB2；V18

SEQ ID NO:39-AB2

SEQ ID NO:40Have the AB2 of joint sequence

SEQ ID NO:41Have the AB2 of joint sequence 2；VR2-801-18

SEQ ID NO:42-AB2m-2

SEQ ID NO:43Have the AB2m-2, V18H2 of joint sequence

SEQ ID NO:44-AB3,V45

SEQ ID NO:45-AB3

SEQ ID NO:46Have the AB3 of joint sequence；V45H1

SEQ ID NO:47Have the AB3 of joint sequence 2；VR2-801-45

SEQ ID NO:48-V45H2

SEQ ID NO:49-AB4；V38

SEQ ID NO:50-AB4

SEQ ID NO:51Have the AB4 of joint sequence

SEQ ID NO:52Have the AB4 of joint sequence 2；VR2-38

SEQ ID NO:53-AB4c；V38H3

Or with its have at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, the sequence of at least 92%, at least 93%, at least 94% or at least 95% identity, or the sequence substantially same with it.

The joint sequence for being suitable for single domain antibody of the invention can be selected from GSEQ (SEQ ID NO:54), GSDEE (SEQ ID NO:55)、GSEEEDDDG(SEQ ID NO:56)、 GSEEEDDDGKK(SEQ ID NO:57)、GSEQKGGGEEDDG (SEQ ID NO:58)、GSEQKLISEEDLNHHHHH(SEQ ID NO:59)、 GSEQKLISEEDLNHHHHHH(SEQ ID NO:60)、GSEEDDDEEK(SEQ ID NO:61)、GSEQKGGGEEDDEE(SEQ ID NO:62)、 GSEQKLISEEDLNGGGEDDEEG (SEQ ID NO:63), GSEQKLISEEDLNGGGEDEG (SEQ ID NO:64) and GSEQKGGGDEDG (SEQ ID NO:65).In some terms, joint sequence can also include C-terminal cysteine, such as GSEQKGGGEEDDGC(SEQ ID NO:66)、 GSEQKLISEEDLNGGGEDDEEGC(SEQ ID NO:67)、 GSEQKLISEEDLNGGGEDEGC(SEQ ID NO:68) and GSEQKGGGDEDGC(SEQ ID NO:69).With these connectors The similar sequence of sequence can be used for herein.For example, KK is suitable joint sequence and any comprising SEQ ID NO:54-69 Those of.

CAR includes the VEGFR-2 bound fraction in conjunction with VEGFR-2, its epitope, its segment or above-mentioned variant, and It also include activated immune cell structural domain.When being expressed by immunocyte, VEGFR-2 bound fraction is extracellular domain or thin A part of extracellular domain, and activated immune cell structural domain is intracellular signaling domain or intracellular signaling domain A part, usually a part of T cell antigen receptor complex ζ chain (such as CD3 ζ).Costimulatory signal area can also be by It is included in intracellular domain, and is the cell surface molecule other than antigen receptor or its ligand, is that lymph is thin Needed for effective response of the born of the same parents to antigen.Compartment (also referred to as hinge fraction) is generally included in extracellular domain To allow VEGFR-2 bound fraction to be effectively bonded to its epitope.Intracellular and extracellular domain is by crossing over cytoplasma membrane Transmembrane domain connection.

The representative non-limiting structure of CAR of the invention includes that the single domain of the VEGFR-2 of tumor cell is anti- The intracellular domain (referred to as first generation CAR) of the TCR compound CD3 ζ of body, transmembrane domain and activation T cell.One side Face, CAR include the sequence of SEQ ID NO:78:

Or its segment or its variant.

As understood by those skilled in the art, the nucleic acid sequence of such single domain antibody can be obtained by a variety of methods. For example, nucleic acid sequence can be the sequence of SEQ ID NO:79:

The surface antigen for expressing the T cell Direct Recognition tumour cell of CAR, independent of Main Tissues phase on tumour cell The expression of capacitive antigen I class, and activating T cell simultaneously, so that the T cell for expressing CAR can effective killing tumor cell.

In order to enhance the ability of first generation CAR activating T cell, by the cell as the CD28 of the costimulatory molecules of T cell Intracellular domain is connect with first generation CAR, so as to prepare second generation CAR.It will be derived from as tumor necrosis factor (TNF) receptor The intracellular domain and first generation CAR of the (for example) CD137 (4-1BB) or CD134 (OX40) of superfamily are connected in series, thus Third generation CAR can also be prepared.Therefore, the present invention includes the CAR molecule of many targeting VEGFR-2.

CAR of the invention includes its funtion part.When being related to CAR, term " funtion part " means CAR's of the invention Any part or segment, the part or segment retain the bioactivity of CAR, and wherein this is part CAR (parental generation CAR).Function Part includes, for example, retaining compared with parental generation CAR and identifying target cell with similar degree, identical degree or higher degree Or detection, the part those of the CAR of ability for treating or preventing disease.About parental generation CAR, funtion part can include, such as About 10%, 25%, 30%, 50%, 68%, 80%, 90%, 95% or more of parental generation CAR.

In the amino terminal or carboxyl terminal of part or in this two end, funtion part can include additional amino acid, Additional amino acid is not in the amino acid sequence of parental generation CAR.It is desired, additional amino acid not interference function part Biological function, such as identification target cell, detection cancer, treatment or prevention cancer etc..It is more desirable that the biology with parental generation CAR Expression activitiy, additional amino acid enhance bioactivity.

It is the functional variant thereof of the CAR of invention as described herein, polypeptide and albumen included by the scope of the present invention.Herein Term " functional variant thereof " used mean with parental generation CAR, more peptide or proteins are basic or significant identity or similarity The CAR of sequence, more peptide or proteins, the functional variant thereof retains CAR, the bioactivity of more peptide or proteins (is tied with VEGFR-2 Close), wherein CAR, more peptide or proteins are variants.Functional variant thereof includes, such as compared with parental generation CAR, more peptide or proteins, retains With the CAR as described herein of the ability of similar degree, identical degree or higher degree identification target cell, more peptide or proteins Those of (parental generation CAR, more peptide or proteins) variant.About parental generation CAR, more peptide or proteins, for example, functional variant thereof can be with Parental generation CAR, more peptide or proteins amino acid sequence about 30%, 50%, 75%, 80%, 90%, 98% or more it is same Property.

For example, functional variant thereof can include parental generation CAR, polypeptide or egg with the substitution of at least one conserved amino acid White amino acid sequence.Alternatively or additionally, functional variant thereof can be comprising taking at least one nonconserved amino acid The amino acid sequence of the parental generation CAR in generation, more peptide or proteins.In this case, for nonconserved amino acid substitution, usually not Interference or the bioactivity for not inhibiting functional variant thereof.Nonconserved amino acid replaces the biology that functional variant thereof can be enhanced living Property, so that the bioactivity of functional variant thereof increases compared with parental generation CAR, more peptide or proteins.

The amino acid substitution of CAR of the invention is that typical conserved amino acid replaces.Conserved amino acid substitution is this field In it is known, and including amino acid wherein with certain physically and/or chemically characteristics and another with same or similarization The amino acid substitution that the amino acid of or physical characteristic swaps.For example, conserved amino acid substitution can be acidic amino acid Replace (such as Asp or Glu), the amino acid with non-polar sidechain by another with non-polar sidechain by another acidic amino acid Amino acid substitution (such as Ala, Gly, Val, Ile, Leu, Met, Phe, Pro, Trp, Val etc.), basic amino acid it is another Basic amino acid replaces (Lys, Arg etc.), the amino acid with polar side chain by another amino acid substitution with polar side chain (Asn, Cys, Gln, Ser, Thr, Tyr etc.) etc..

CAR, more peptide or proteins are substantially made of specific amino acid sequence as described herein, so that other components Such as other amino acid will not substantial varying functionality variant bioactivity.

CAR, polypeptide and the albumen (including Functional portions and functional variant thereof) of embodiment of the present invention can be any Length, can include any amount of amino acid, and condition be that CAR, more peptide or proteins (or its Functional portions or functional become Body) retain their bioactivity, for example, with the ability of VEGFR-2 specific binding, treating or preventing the ability of host disease Deng.For example, polypeptide can be about 50 to about 5000 amino acid lengths, such as 50,70,75,100, 125,150,175,200,300,400,500,600,700,800,900,1000 or more The length of multiple amino acid.In this regard, polypeptide of the invention also includes oligopeptides.

CAR, polypeptide and albumen (including Functional portions of the invention and functional variant thereof) energy of embodiment of the present invention Enough synthesizing amino acids comprising the one or more naturally occurring amino acid of substitution.Such synthesizing amino acid is as is generally known in the art , and including for example, cyclohexanecarboxylic acid, nor-leucine, α amino n-capric acid, homoserine, S- acetylamino methyl- Cysteine, trans- -3- hydroxyl proline and trans- -4- hydroxyl proline, 4- aminophenylalanine, 4- nitrophenylalanine, 4- chlorophenyl alanine, 4- carboxyl phenyl alanine, beta-phenyl serine, beta-hydroxyphenyl alanine, phenylglycine, Alpha-Naphthyl Alanine, Cyclohexylalanine, Cyclohexylglycine, indoline -2- carboxylic acid, 1,2,3,4- tetrahydroisoquinoline -3- carboxylic acid, ammonia Propylmalonic acid, amidomalonic acid Dan Xiangan, N '-phenyl-N '-methyl-lysine, N ', N '-dibenzyl-lysine, 6- hydroxyl rely (camphane drops in 2- amino -2- by propylhomoserin, ornithine, alpha-amido cyclopentane-carboxylic acid, alpha-amido cyclohexane-carboxylic acid, α-cycloheptyl alkanamine carboxylic acid, α - Alkane)-carboxylic acid, α-gamma-diaminobutyric alpha acid, alpha-beta-diaminopropionic acid, phenyl Gamma Amino Butyric Acid and α-Terleu.

CAR, polypeptide and the albumen (including Functional portions and functional variant thereof) of embodiment of the present invention can be glycosyls Changing, amidated, carboxylated, phosphorylation, esterification, N- is acylated, be for example cyclized via disulfide bond or conversion For acid-addition salts and/or optionally dimerization or polymerization or combination.

VEGFR-2 bound fraction

Typical aspect, CAR as described herein to VEGFR-2, its segment, its epitope and any VEGFR-2 above-mentioned, its Segment, its epitope variant have specificity.VEGFR-2 bound fraction of the invention makes it and carries on cell/tumor surface VEGFR-2 is combined with desired affinity, is led to (1) receptor down-regulated and is reduced angiogenesis and (2) activated immune cell, wherein VEGFR-2 bound fraction is provided to cause cellular cytoxicity activity in tumor microenvironment and discharge cell factor, and is further expanded Increase.

It is not wishing to be bound by theory, it is believed that the antibody/VEGFR-2 epitope interaction has the affinity of advantageous level (less high and less low) enables antibody to combine the epitope on the first cell and activating cell killing, then proceedes to combine Second or other epitopes on other cells and activate other cell killings.

Therefore, there is also described herein CAR, and it includes the complementary determining regions (CDR) 1 in VEGFR-2 bound fraction；CDR2 And CDR3, wherein antibody or its segment are VEGFR-2 specificity.

Term " antibody " and " antibody fragment " (" its segment ") are as defined above.As previously mentioned, antibody or its segment can be with It is sd Ab.Sd Ab can be (for example, the planting from Camelidae (Camelidae)) in Camelidae source or from Camelidae V_HH, therefore Camelidae framework region can be based on；Alternatively, the upper CDR can be transplanted to V_NAR、V_HHOr V_LOn framework region.In In another alternative scheme, above-mentioned hypervariable loop can be transplanted to the frame of other kinds of antibody fragment (Fv, scFv, Fab) In frame area.

Present invention also contemplates that being such as, but not limited to CDR grafting and frosting using any appropriate method known in the art " humanization " antibody fragment.The humanization of antibody or antibody fragment includes with the people couple such as found in mankind's consensus sequence The amino acid in object alternative sequence is answered, without losing antigen binding capacity or specificity；When being introduced into human individual, this side Method reduces antibody or the immunogenicity of its segment.It, can be by one defined herein or more than one during CDR transplanting People variable region (V is transplanted in a heavy chain CDR fusion_HAnd V_L) or other people antibody fragment framework regions (Fv, scFv, Fab).In In such situation, the conformation of one or more than one hypervariable loop is remained, and also retains sdAb to its target (i.e. Toxin A and B) affinity and specificity.

CDR transplanting: U.S. Patent No. 6,180,370, U.S. Patent No. 5,693 is described at least following patent, No. 761, U.S. Patent No. 6,054,297, U.S. Patent No. 5,859,205 and European Patent No. 626390 (are led to herein Disclosure of which is integrally incorporated by the mode for crossing reference).Frosting is also referred to as " Variable region surface reconditioning " in the art, relates to And the solvent exposure position of humanized antibody or segment；Therefore, the hiding non-humanization that reservation may be important to CDR conformation is residual Base, while minimizing a possibility that immune response for being directed to solvent exposed region.Frosting is described at least following patent: the U.S. Patent the 5,869,619th, U.S. Patent No. 5,766,886, U.S. Patent No. 5,821,123 and European Patent No. No. 519596 (being herein by reference integrally incorporated disclosure of which).Those skilled in the art will be sufficiently familiar with system The method of standby such humanized antibody segment.

Substantially same sequence may include one or more conserved amino acid mutations.The one of reference sequence known in the art A or multiple conserved amino acid mutations can produce to be become in physiology, chemistry or functional character without essence compared with reference sequence The mutant peptide of change；In such cases, reference sequence and mutant nucleotide sequence are considered as " substantially same " polypeptide.Conserved amino acid Mutation may include the addition, deletion or substitution of amino acid；Conserved amino acid substitution is defined herein as amino acid is residual Base is substituted by another amino acid residue with similar chemical property (such as size, charge or polarity).

In non-limiting example, conservative variants can be amino acid substitution.Such conserved amino acid substitution can be by alkali Property, neutrality, hydrophobicity or acidic amino acid are substituted by the another kind in same group.Term " basic amino acid " means side chain pK value Hydrophilic amino acid greater than 7, it is usually positively charged at physiological ph.Basic amino acid includes histidine (His or H), essence Propylhomoserin (Arg or R) and lysine (Lys or K).Term " neutral amino acid " (also referred to as " polar amino acid ") means to have in life The hydrophilic amino acid of uncharged side chain under pH is managed, but there are two the shared electronics of atom to by one of atom for its tool At least one key more closely kept.Polar amino acid includes serine (Ser or S), threonine (Thr or T), cysteine (Cys or C), tyrosine (Tyr or Y), asparagine (Asn or N) and glutamine (Gln or Q).Term " hydrophobic amino Acid " (also referred to as " nonpolar amino acid ") means to include the normalized shared hydrophobicity scale according to Eisenberg (1984) Show the hydrophobic amino acid greater than zero.Hydrophobic amino acid includes proline (Pro or P), isoleucine (Ile or I), benzene Alanine (Phe or F), valine (Val or V), leucine (Leu or L), tryptophan (Trp or W), methionine (Met or M), Alanine (Ala or A) and glycine (Gly or G)." acidic amino acid " means hydrophilic amino acid of the side chain pK value less than 7, It is usually negatively charged at physiological ph.Acidic amino acid includes glutamic acid (Glu or E) and aspartic acid (Asp or D).

Sequence identity is used to evaluate the similitude of two sequences；By calculating when comparison two sequences are to obtain residue position Identical residue percentage determines when maximum correspondence between setting.Any known method can be used, and to carry out the sequence of calculation same Property；For example, computer software can be used for sequence of calculation identity.It is not intended to be restricted, it can be same by the software sequence of calculation One property, such as safeguarded by bioinformatics research institute, Switzerland (Swiss Institute of Bioinformatics) (and Found in ca.expasy.org/tools/blast/) NCBI BLAST2 service, BLAST-P, Blast-N or FASTA-N, Or any other suitable software known in the art.

Substantially it is same that same sequence of the invention can be at least 85%；In another example, substantially same sequence Column can be on amino acid levels with sequence as described herein at least 70,75,80,85,90,95,96,97,98,99 or 100% (or any percentage therebetween) is same.Specific aspect, substantially same sequence remain the activity of reference sequence And specificity.In a not limiting embodiment, the difference of sequence identity may be as caused by conserved amino acid mutation.

Single domain antibody of the invention or its segment can also include other sequence to help recombinant antibodies or its segment Expression, detection or purifying.Any such sequence well known by persons skilled in the art or label can be used.For example, but being not intended to Be it is restrictive, antibody or its segment may include targeting or signal sequence (such as, but not limited to ompA), detection label, example Property label box includes Strep label or its any variant；See, e.g., U.S. Patent No. 7,981,632, His label has There are Flag label, Xpress label, Avi label, calmodulin label, the polyglutamic acid label, HA of sequence motifs DYKDDDDK Label, Myc label, Nus label, S label, SBP label, Softag 1, Softag 3, V5 label, CREB binding protein (CBP), glutathione S-transferase (GST), maltose-binding protein (MBP), green fluorescent protein (GFP), thioredoxin Label or any combination thereof；Purification tag (such as, but not limited to His5 or His6), or combinations thereof.

In another example, sequence in addition can be biotin recognition site, and such as Cronan et al. is in WO 95/ In 04069 or Voges et al. is described in the WO/2004/076670.Also as known to those skilled, it can will connect Header sequence is used in combination with other sequence or label.

More specifically, label box may include extracellular component, it being capable of high-affinity or affinity and antibody specificity In conjunction with.In single chain fusion protein structure, label box can be located at (a) close to the amino terminal of connection sub-district, (b) be inserted in and connect Between header sequence module and jointing block (d) is inserted in (c) close to the carboxyl terminal of binding structural domain in conjunction with knot It is connect between structure domain (such as scFv) and effect domain and by binding structural domain (such as scFv) with effect domain, (e) it is inserted between binding structural domain subunit and connects binding structural domain subunit, or (f) in the amino terminal of single chain fusion protein. In certain embodiments, one or more connection amino acid can be arranged between label box and hydrophobic parts and will be marked Label box is connect with hydrophobic parts, or setting connects between label box and connection sub-district and by label box with sub-district is connect, Or it is arranged between label box and joint sequence module and connects label box and joint sequence module, or be arranged in label box It is connect between binding structural domain and by label box and binding structural domain.

Transmembrane domain

Specific aspect, CAR include transmembrane domain, are merged with the extracellular domain of CAR and intracellular domain. On the one hand, using natively transmembrane domain associated with a structural domain in CAR.In some cases, can pass through Amino acid substitution selects or modifies transmembrane domain, to avoid the cross-film of such structural domain and identical or different surface membrane protein Structural domain combines, to minimize the interaction with other members of receptor complex.

Transmembrane domain can be derived from natural origin or synthesis source.In the case where source is natural, structural domain can be with Derived from any embrane-associated protein or transmembrane protein.Transmembrane region specifically used in the present invention can be derived from (i.e. including at least it Transmembrane region): α, β or ζ chain of T cell receptor, CD28, CD3 ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37,CD64,CD80,CD86,CD134,CD137,CD154.In general, the transmembrane domain in CAR as described herein is CD28 Transmembrane domain.

Alternatively, transmembrane domain can be synthesis, in this case, it will mainly include hydrophobic residue, such as Leucine and valine.In general, can find phenylalanine, tryptophan and figured silk fabrics ammonia in each end of the transmembrane domain of synthesis The triplet of acid.Optionally, normal length is the short oligopeptides joint sequence or polypeptide linker sequence of 2 to 10 amino acid, can To form the connection between the transmembrane domain of CAR and cytoplasmic signaling domain.Glycine-serine doublet provides special Suitable joint sequence.

Intervening sequence structural domain

Between the extracellular domain and transmembrane domain of CAR, or in the cytoplasmic domain and transmembrane domain of CAR Between, intervening sequence structural domain, also referred to as hinge domain can be mixed.As used herein, term " intervening sequence structure Domain " generally means that any oligopeptides or polypeptide, and function is by the extracellular domain or cell in transmembrane domain and polypeptide chain The connection of matter structural domain, and VEGFR-2 binding structural domain is promoted from cell surface.Intervening sequence structural domain may include up to 300 amino acid, usually 10 to 100 amino acid, and it most typically is 25 to 50 amino acid.Intervening sequence may include with It is one of lower, such as: human IgG1 Fc structural domain, IgG1 hinge, IgG1 hinge-CD8 stem, CD8 stem, IgG1 hinge-CD28 stem and CD28 stem.

Cytoplasmic domain

The cytoplasmic domain of CAR as described herein or other intracellular signaling domain are responsible for activation and have wherein been placed At least one normal effect subfunction of the immunocyte of CAR.Term " effector function " means the dedicated functions of cell.T is thin The effector function of born of the same parents for example can be cell lysis activity or the auxiliary activity including the secretion of cell factor.Therefore, Term " intracellular signaling domain " means the portion for the albumen that transduction effector function signal and guides cell to execute dedicated functions Point.Although entire intracellular signaling domain usually can be utilized, in many cases, it is not necessary to use whole chain.It is using In the case of the truncation part of intracellular signaling domain, such truncation part can be used and replace complete chain, as long as it transduces Effector function signal.Therefore, term intracellular signaling domain means to include being enough effector function signal of transduceing Any truncation part of intracellular signaling domain.

The representative instance of intracellular signaling domain for CAR described herein includes the cytoplasm of T cell receptor (TCR) Sequence and antigen receptor participation after cooperation enabling signal transduction coreceptor and these sequences any derivative or Variant and any composition sequence with identical function ability.

Level-one cytoplasmic signal sequence is with stimulation mode or with the primary activation of suppressor mode regulation TCR compound.With thorn The level-one cytoplasmic signal sequence that sharp mode works can contain signal motif, be referred to as and be based on immunity receptor tyrosine-kinase Motif or ITAM living.

The example of ITAM containing level-one cytoplasmic signal sequence specifically used in the present invention includes derived from below Those ITAM:TCR ζ, FcR γ, FcR β, CD3 γ, CD3 δ, CD3 ε, CD5, CD22, CD79a, CD79b and CD66d.Special allusion quotation Type, the cytoplasmic signal molecule in CAR as described herein include the cytoplasmic signal sequence from CD3 ζ.

The cytoplasmic domain of CAR can be designed as itself including CD3- ζ signal domain by typical aspect, or Include the CD3- ζ letter combined with any other desired cytoplasmic domain useful in the context of CAR described herein Number structural domain.For example, the cytoplasmic domain of CAR can include CD3 ζ chain part and one or more costimulatory signals area. Costimulatory signal fauna refers to a part of the CAR of the intracellular domain comprising costimulatory molecules.Costimulatory molecules are in addition to anti- Cell surface molecule except original receptor or its ligand is needed for effective response of the lymphocyte to antigen.Such molecule Example include that CD27, CD28,4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function correlation are anti- - 1 (LFA-1) of original, CD2, CD7, LIGHT, NKG2C, B7-H3 and the ligand etc. with CD83 specific binding.

It can be with random or specified sequence by the cytoplasm signal sequence in the cytoplasm signal section of CAR described herein Column are connected to each other.Optionally, short oligopeptides joint sequence or polypeptide linker sequence of the normal length between 2 and 10 amino acid can It is formed bonded.Glycine-serine doublet provides specially suitable joint sequence.

On the one hand, cytoplasmic domain is configured to the signal domain comprising CD3- ζ and the signal structure of CD28 Domain.On the other hand, cytoplasmic domain is designed to the signal domain comprising CD3- ζ and the signal domain of 4-1BB.It is another Aspect, cytoplasmic domain are designed to the signal domain comprising CD3- ζ and the signal domain of CD28 and 4-1BB.

On the one hand, the cytoplasmic domain in CAR as described herein is designed to the signal comprising CD28 and/or 4-1BB The signal domain of structural domain and CD3- ζ.

Carrier

This document describes the carriers for being wherein inserted into DNA of the invention.Carrier derived from retrovirus such as slow virus is real The suitable tools of existing long-term gene transfer, because they allow the steady in a long-term of transgenosis to integrate and its numerous in daughter cell It grows.Slow virus carrier has the added advantage that relative to derived from the carrier of oncogenic retrovirus such as murine leukemia virus, because They can transduce non-proliferative cell such as liver cell.They also have the additional advantage of low immunogenicity.

In brief, usually by the nucleic acid of coding CAR polypeptide or part thereof is operably connected with promoter and incite somebody to action The expression of the natural or synthetic nucleic acid of coding CAR is realized in construct incorporation expression vector.Carrier can be suitable for duplication and Integrate eucaryote.Typical cloning vector contains transcription and translation terminator, homing sequence and for regulating and controlling desired core The promoter of acid sequence expression.

Scheme is delivered using standard gene, expression construct of the invention can also be used for nucleic acid immunization and gene Therapy.Method for gene delivery is known in the art.See, e.g., U.S. Patent No. 5,399,346, the 5th, 580, No. 859, the 5th, 589, No. 466 are integrally incorporated herein by reference.On the other hand, the present invention provides Gene therapy vector.

Nucleic acid (SEQ ID NO:31-53 or 80) can be cloned into the carrier of many types.For example, can be by nucleic acid It is cloned into carrier, including but not limited to plasmid, phasmid, phage-derived object, animal virus and clay.It is of special interest Carrier includes expression vector, replicating vector, probe generation carrier and sequencing vector.

Furthermore, it is possible to which expression vector is supplied to cell in the form of viral vectors.Viral vector technology is in the art It is known that knowing, and for example it is described in Sambrook et al. (2001, Molecular Cloning:A Laboratory Manual (molecular cloning: laboratory manual), Cold Spring Harbor Laboratory, New York) and in other virology and molecular biology manual.The virus that can be used as carrier includes but is not limited to retrovirus, gland Virus, adeno-associated virus, herpesviral and slow virus.It works at least one organism in general, suitable carrier contains Replication orgin, promoter sequence, convenient restriction endonuclease site and one or more selectable markers (for example, WO 01/96584；WO 01/29058；With U.S. Patent No. 6,326,193, herein by reference by it Content is integrally incorporated).

Many systems based on virus for by gene transfer into mammalian cell are developed.For example, inverse Retroviral is the platform that genes delivery system is provided convenience.Techniques known in the art is able to use to insert selected gene Enter in carrier and is packaged in retroviral particle.Then recombinant virus and in vivo or ex vivo delivered is to individual can be separated Cell.Many retroviral systems are as known in the art.In some terms, using adenovirus vector.Many adenovirus Carrier is known in the art.On the one hand, using slow virus carrier.

The frequency of other promoter element such as enhancer regulatory transcription starting.In general, these are located on initiation site The region of trip 30 to 110bp, although having shown that function element of many promoters also containing initiation site downstream recently.Starting Interval between subcomponent is usually flexible, therefore keeps promoter function when element is inverted relative to each other or is moved. In thymidine kinase (tk) promoter, the interval between promoter element can increase to apart before activity is begun to decline 50bp.According to promoter, it appears that discrete component can be cooperateed with or independently be worked with activated transcription.

One example of suitable promoter is early stage cytomegalovirus (CMV) promoter sequence immediately.The promoter sequence It is strong constitutive promoter sequence, the high-level table for any polynucleotide sequence being operably connected with it can be driven It reaches.Another example of suitable promoter is -1 α of the elongation growth factor (EF-1 α).It is also possible, however, to use other composing types open Promoter sequences, including but not limited to simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), people exempt from Epidemic disease defective virus (HIV) long terminal repeats (LTR) promoter, MoMuLV promoter, avian leukosis viruses promoter, Epstein-Barr virus immediate early promoter (Epstein-Barr virus immediate early promoter), Rous sarcoma virus promoter and human gene promoter, such as, but not limited to actin promoter, myosin starting Son, Hemoglobin promoter and creatine kinase promoter.In addition, the present invention should not necessarily be limited by using constitutive promoter.Induction type Promoter is also considered as part described herein.The use of inducible promoter provides molecular switch, works as and needs this Class can start the expression for the polynucleotide sequence that it is operably connected when expressing, or can close when not needing expression Expression.The example of inducible promoter includes but is not limited to metallothionein promoter, Glucocorticoid promoter, progesterone starting Son and tetracycline promoter.

In order to assess the expression of CAR polypeptide or part thereof, the expression vector of cell to be introduced can also contain selection marker Object gene or reporter gene or both, in order to from seek by the transfected or infected cell mass of viral vectors identify and select Expression cell.Other aspects, selection marker can be carried on individual DNA fragmentation and be used for cotransfection program.It can It enables to express in host cell so that both selection marker and reporter gene are flanked regulating and controlling sequence appropriate.It is useful Selection marker include such as antibiotics resistance gene, neo etc..

Reporter gene is used to identify the cell of potential transfection and is used to evaluate the function of regulating and controlling sequence.In general, report base Because being to be not present in recipient organism or tissue or not by recipient organism or tissue expression and encode the gene of polypeptide, Expression is showed by some characteristic such as enzymatic activitys for being easy to detect.After DNA is introduced recipient cell, when appropriate Between measure reporter gene expression.Suitable reporter gene may include coding fluorescence element enzyme, beta galactosidase, chloramphenicol second Acyltransferase, the gene of secreted alkaline phosphatase or green fluorescence protein gene are (for example, Ui-Tei et al., 2000FEBS Letters (FEBS flash report) 479:79-82).Suitable expression system is well-known, and can be by using known technology Preparation commercially obtains.In general, the construct with minimum 5 ' flanking regions of display reporter gene highest expression is reflected It is set to promoter.Such promoter region can be connect with reporter gene, and be used to evaluate reagent and adjust promoter driving The ability of transcription.

It is known in the art that gene, which is introduced into cell, and is expressed the method in cell.Above and below expression vector Carrier easily can be introduced host cell, such as mammal, bacterium, yeast by any method of this field by Wen Zhong Or insect cell.For example, expression vector can be transferred in host cell by physics, chemistry or biological means.

For by polynucleotides introduce host cell physical method include calcium phosphate precipitation, lipofection, particle bombardment, Microinjection, electroporation etc..For generate include carrier and/or Exogenous Nucleic Acid cell method be it is well known in the art that 's.See, e.g., Sambrook et al. (2001, Molecular Cloning:A Laboratory Manual (molecules gram It is grand: laboratory manual), Cold Spring Harbor Laboratory, New York).For polynucleotides to be introduced host The typical method of cell is calcium phosphate transfection.

Biological method for herbicide-tolerant polynucleotide to be introduced to host cell includes using DNA and RNA carrier.Virus Carrier and especially retroviral vector, it has also become gene is inserted into mammal such as human cell most to be made extensively Method.Other viral vectors can be derived from slow virus, poxvirus, herpes simplex virus I, adenovirus and adeno-associated virus Deng.See, e.g., U.S. Patent No. 5,350, No. 674 and the 5th, 585, No. 362.

Chemical means for polynucleotides to be introduced to host cell include dispersion system of colloid, and such as macromolecular is compound Object, Nano capsule, microballoon, pearl and the system based on lipid, including oil-in-water emulsion, micella, mixed micelle and liposome.It is used as The exemplary colloid system of in vitro and in vivo delivery vector is liposome (for example, artificial membrane vesicles).

Using non-viral delivery systems, exemplary delivery carrier is liposome.Consider to use lipid formulations Nucleic acid is introduced into host cell (external, in vitro or internal).On the other hand, nucleic acid and lipid can be associated.It can will be with rouge The nucleic acid that matter is mutually associated is encapsulated in the aqueous interior of liposome, is dispersed in the double-layer of lipoid of liposome, by with liposome and widow The connection molecule that nucleotide mutually associates is connect with liposome, is embedded in liposome, with lipid bluk recombination, is dispersed in containing lipid Solution in, mix with lipid, and lipid binding, be included in lipid with suspension form, is included in micella or and micella It is compound, or otherwise associate with lipid.Lipid, lipid/DNA or the relevant composition of lipid/expression vector are not limited to molten Any specific structure in liquid.For example, they can exist using double-layer structure, as micella or with " collapsing " structure.They It can also simply spread in the solution, it is possible to create the non-uniform aggregation of size or shape.Lipid is fatty material, can To be natural or synthetic lipid.For example, lipid include the fat drop being naturally present in cytoplasm and containing length The compounds of chain aliphatic series hydrocarbons and their derivates, such as fatty acid, alcohols, amine, alkamine and aldehydes.

The lipid for being suitble to use can be obtained from commercial source.For example, two can be obtained from Sigma, St. Louis, Mo. Dimyristoylphosphatidycholine (" DMPC ")；Di(2-ethylhexyl)phosphate spermaceti rouge can be obtained from the laboratory K&K (Plainview, N.Y.) ("DCP")；Cholesterol (" Choi ") can be obtained from Calbiochem-Behring；It can be from Avanti Polar Lipids Company's (Birmingham, Alabama) obtains GLYCEROL,DIMYRISTOYL PHOSPHATIDYL (" DMPG ") and other lipids.It can be about -20 The chloroform or chloroform/methanol liquid storage of lipid are stored at DEG C.Chloroform is used as unique solvent, because it is easier to steam than methanol Hair." liposome " is generic term, cover by generate closed double-layer of lipoid or aggregation formed it is various single and more Layer lipid carrier.Liposome can be characterized as with imitated vesicle structure, the imitated vesicle structure has Lipid bilayer membranes and internal aqueous Medium.Multilamellar liposome has the multiple lipid layers separated by aqueous medium.When phosphatide is suspended in excessive aqueous solution, They are spontaneously formed.Lipid composition is undergone before forming enclosed construction from resetting, and water and molten is captured between double-layer of lipoid The solute (Ghosh et al., 1991Glycobiology 5:505-10) of solution.However, also cover in the solution have with it is normal The composition of imitated vesicle structure different structure.For example, lipid can be presented micellar structure or only as the uneven poly- of lipid molecular Collective exists.Also contemplate liposome-nucleic acid compound.

No matter for Exogenous Nucleic Acid to be introduced host cell or exposes cells to inhibition of the invention in other ways The method of agent can carry out many measure to confirm the presence of recombinant DNA sequence in host cell.Such measurement includes example Such as, " molecular biology " well known to those skilled in the art measurement, such as Southern and Northern trace, RT-PCR and PCR；" biochemistry " measurement, such as detect particular peptide existence or non-existence, such as by immunology means (ELISA and Western blot) or by it is as described herein measurement to identify the reagent fallen into range described herein.

Transposons/transposase system

Typical method for DNA to be introduced to cell includes DNA condensation reagent such as calcium phosphate, polyethylene glycol etc., contains lipid Reagent such as liposome, multi-layer vesicles etc. and virus-mediated strategy.

However, all these methods have its limitation.For example, in the presence of with DNA condensation reagent and virus-mediated strategy Relevant size limitation.Furthermore it is possible to which the amount for the nucleic acid being transfected into cell is restricted in viral strategy.And not all side Method both contributes in the nucleic acid that will be delivered insertion cellular nucleic acid, although and DNA method of condensing and reagent containing lipid is opposite holds Easily preparation, but it may be labor-intensive that nucleic acid, which is inserted into viral vectors,.In addition, virus-mediated strategy can be carefully Born of the same parents' type or tissue type specificity, and when used in vivo, immunology can be generated using virus-mediated strategy Problem.

In order to overcome these problems, a suitable tool is transposons.Transposons or can transposable element include its upstream and Downstream has (short) nucleic acid sequence of terminal repeat.Active transposons coding promotes nucleic acid excision and insertion target DNA sequence The enzyme of column.

At present it is known that two class transposons, i.e. I class and II class transposons.

I class transposons, and by title retrotransposon or retroposon, including retrovirus sample retrotransposon and Non- retrovirus sample retrotransposon.They by replicate oneself and by copy paste back genome multiple positions come It works.Initially, self-replication is RNA (transcription) by retrotransposon, but is not translated, but passes through reverse transcriptase Rna replicon is DNA and turned back in genome by (usually being encoded by transposons itself).The Typical Representative of I class transposons includes Such as Copia (drosophila), Ty1 (yeast), THE-1 (mankind), Bs1 (corn), F- element, L1 (mankind) or Cin4 (corn).

As the first step, it is necessary to II class transposons is transfected into cell using standard method (such as virus infection etc.). Later, the II class transposons, also referred to as " only DNA transposons " and by cut and paste mechanism rather than by duplication glue Patch uses transposase to move in the mechanism.Different types of transposase can work in different ways.It is certain can With in conjunction with any part of DNA molecular, and target site can be located at any position, and other sites and particular sequence knot It closes.Then transposase shearing target site discharges transposons and is connected to target site to generate cohesive end.Typical II class Represent includes P element (drosophila), Ac-Ds (corn), TN3 and IS1 (Escherichia coli (E.coli)), Tam3 (toad's-mouth) etc..

Particularly, using II class transposons, the swivel base enzymatic transposons of component numbering from the excision in its home position simultaneously Promote its be inserted into genome in other positions (Plasterk, 1996 Curr. Top.Microbiol.Immunol.204, 125-143).The autonomous member of swivel base sub-family can express active transposase-swivel base trans-acting factor-and therefore energy Enough voluntarily swivel bases.Non-autonomous element has the transposase gene of mutation, but can retain cis-acting DNA sequence.These cis- works Inverted terminal repeat sequence (IR) is also referred to as with DNA sequence dna.Certain inverted repeats may include one or more direct Repetitive sequence.Usually by the inverted terminal repeat sequence (IR) of these sequence embedded components, this is existed from another member Needed for being mobilized in the case where the complementary transposase of part.Up to the present, not dynamic from vertebra other than Tol2 (seeing below) Single autonomous element is separated in object；All swivel base increment sequences are all defective, it is clear that are since one is called " vertical mistake Caused by the process of work " (Lohe et al., 1995 Mol.Biol.Evol. 12,62-72).According to a systematic growth model (Hartl et al., 1997 Trends Genet.13,197-201), non-autonomous element and autonomous element in eukaryotic gene groups Ratio due to swivel base trans-complementation property and increase.The process causes transposase active in genome to generate the final of copy Disappearance is inevitable state.Therefore, DNA transposons can be considered as the temporary component part of genome, in order to avoid disappearing It loses, it is necessary to find the method that oneself is established in new host.In fact, the level gene transmitting between species is considered as swivel base Son evolve in one of significant process (Lohe et al., 1995, ibid and Kidwell, 1992.Curr.Opin.Genet Dev.2, 868-873)。

It is capable of the natural process of dummy level gene transfer in laboratory conditions.In plant, Ac/Ds and Spm family Transposons by routine transfection into allogenic species (Osborne and Baker, 1995 Curr.Opin.Cell Biol.7,406-413).However, in animal, due to the factor for needing natural host to generate, by active Transposon System from The major obstacle that one species are transferred to another species has the species specificity of swivel base.

Transposon System as discussed above is likely to occur in vertebrate and invertebrate system.In vertebrate In, the DNA transposons moving element that is moved by DNA intermediate be the discovery that relative close (Radice, A.D. et al., 1994.Mol.Gen.Genet.244, 606-612).From that time, from different fish species, xenopus and the mankind It is prominent that the inactive of Td/mariner and hAT (hobo/Ac/Tam) superfamily of eukaryon transposons, height are isolated in genome Member (Oosumi et al., the 1995.Nature 378,873 of change；Ivies et al., 1995.MoI.Gen.Genet.247, 312-322；Koga et al., 1996.Nature 383,30；Lam et al., 1996.J.MoI.Biol.257,359-366 and Lam, W.L. et al., Proc. Natl.Acad Sci.USA 93,10870-10875).

Invertebrate and vertebrate transposons all have the potentiality of model organism transgenic and insertional mutagenesis.It is special Not, the availability of the alternative Transposon System in same species is that genetic analysis opens a possibility that new.For example, Be mobilized in drosophila in the presence of the P element that piggy β ac transposons can be inserted into stabilization (Hacker et al., (2003), Proc Natl Acad Sci U S A 100,7720-5.).Because the system based on P element and based on piggyBac is shown Different insertion point preference (Spradling et al. (1995), Proc Natl Acad Sci U S A 92,10824-30, Hacker et al. (2003), Proc Natl Acad Sci U S A 100,7720-5), can greatly increase can be by swivel base The fly gene dosage of son insertion inactivation.P component carrier has also been used to mariner swivel base through stable germ line transformation In the genome of component insertion Drosophila melanogaster (D.melanogaster) of son.In these transgenic flies, it can study Mariner swivel base is without unexpectedly mobilizing P element (Lohe and Hartl, (2002), Genetics 160,519-26).

It in vertebrate, is currently known and has used three kinds of active transposons: the Tol2 member in green Medaka (medaka) Part, and transposons sleeping beauty (SB) and the The Frog Prince (FP) of reconstruct.Another interesting Transposon System is in vertebrate PiggyBac Transposon System (Ding et al., Cell, 2005).

Tol2 element is the active member of hAT swivel base sub-family in green Medaka.It is by causing Japanese green Medaka (Oryzias Latipes) recessive mutation of the albefaction phenotype of (the small-sized fresh-water fishes in East Asia) and find.It was found that the mutation is due in junket ammonia It is inserted into 5th exon of phytase gene caused by the TE of 4.7-kb long.DNA sequence dna (being named as To/2) class of the element It is similar to the transposons of hAT family, the Acoi of hobo, corn including drosophila and the Tam3 of toad's-mouth.

Sleeping beauty (SB) is the Tc1/mariner sample element from fish, and in the cell of a variety of vertebrates culture High transposition activity is shown in system, embryonic stem cell and internal Mouse Somatic Cells and germ line cell.

The Frog Prince (FP) is also a kind of Tc1/marinner sample element, recently from the northern leopard frog (American leopard frog (Rana pipiens)) genome transposon copies in be reactivated.Using between the identification not of open reading frame catching method Disconnected transposase coding region, and the majority rule common recognition of these sequences discloses and enlivens transposase gene.Therefore, with SB's " resurrection " program is on the contrary, the versus young state of genomic elements to copy the transposons derived from single species in American leopard frog The majority rule common recognition of shellfish is possibly realized.SB and FP transposons is significantly different, and -50% is only shared in their transposase sequence Identity.

Transposons as described above, especially Tol2, SB and FP and piggyback (Ding et al., Cell 2005) It does not interact, therefore Genetic tools can be used as in the presence of others, this has been significantly expanded the practicability of these elements. The gene of these transposons insertion expression rather than the preference of noncoding DNA and may be aobvious to the preference of insertion point in gene It writes different.If it were to be so, the different intercalation models of these Transposon Systems can be utilized in a complementary fashion.Example Such as, different Transposon Systems can be used successively to be transfected into several transgenosis in cell, without unexpectedly and not needing Mobilize the transgenosis being already inserted into ground.In addition, can be passed through by combining different Transposon Systems in full-length genome screens The quantity of the target gene seat of transposon vector mutagenesis can dramatically increase.

Other than the difference of the active variation of swivel base and target site specificity in host, the different structure of various elements Characteristic is also likely to be advantageous in some applications.For example, can be inserted into using transposons come false demonstration gene and find function It can acquired phenotype.Rorth,P.(1996,A modular misexpression screen in Drosophila Detecting tissue-specific phenotypes (detection tissue specificity phenotype drosophila in modularization error list The screening reached) Proc Natl Acad Sci U S A 93,12418-22.) use the induction type for carrying and being directed toward from the element The modified P element transposons of promoter detects tissue to force host gene to be expressed near transposon insertion site Specific phenotypes.The prerequisite of such experimental setup, which is that transposons IR is fair, crosses IR read-through transcription/translation.

As has been explained, DNA transposons has been developed as the gene transfer vector in invertebrate model organism, It and is also recently such in vertebrate.They also become the strong competing of retroviral systems in human gene therapy Strive opponent.As described above, for genetic analysis and treatment method it is the most useful can transposable element (TE) be via " shearing and viscous The II class TE that patch " mechanism moves in host genome, because they are easy to laboratory treatment and have controllable property.Sleep beauty People (hereinafter referred to as " SB ") belongs to the Tcl/mariner family of " cut and paste " transposons.These movable DNA element quilts It simply organizes, the encoding transposase albumen in the genome that they flank inverted terminal repeat sequence (ITR).ITR is carried Swivel base enzyme binding site necessary to swivel base.By by transposase source with carry ITR can swivel base DNA separate, can hold very much It changes places and controls their activity, to generate non-autonomous TE.In such two-component system, transposons can only be turned by supplement The fr3/75 of seat zymoprotein is moved.In fact, any target sequence can be positioned between ITR element according to experiment needs. Swivel base will lead to from cutting off element in carrier DNA and then single copy is integrated into new sequence context.

In general, transposon-mediated chromosome enters and seems than viral methods advantageously, if because on the one hand Compared with virus system, transposons is less conducive to enliven gene and 5 ' control regions, and is therefore less susceptible to mutagenesis, another party Face is physiologically more being controlled due to the special mechanism that their chromosome enters target gene.

SB has proved to be the valuable tool of functional genomics in several vertebrate animal model organisms (Miskey, C, Izsvak, Z., Kawakami, K. and Ivies, Z. (2005)；DNA transposons in vertebrate Functional genomics (the DNA transposons in vertebrate functional genomics) .Cell MoI.Life.Sci.62: 629-641) and show prospect (Ivies, Z. and Izsvak, Z. (2006) .Transposons that human gene therapy applies For gene therapy (transposons for gene therapy)；Curr.Gene Ther.6:593-607).However, for institute There are these applications, the transposition activity of system is the critical issue of availability and efficiency.Although being nowadays known and being described as Functional property and valuable, transposase activity may be to still result in SB system to reach one of factor of its limit.Therefore, turn Active significantly improve of seat may break through current experiment obstacle in two directions.

In some terms, the variant of the hyperactive of SB10 transposase is used for method described herein.Specific aspect, pole Spending active variant can be the variant of WO 2009/003671 (it is integrally incorporated herein by reference) description.Example Such as, the polypeptide of the variant selected from SB10 transposase, comprising with the sequence difference according to the natural SB10 transposase of SEQ ID No.8 The amino acid sequence of 1 to 20 amino acid, 1 to 20 amino acid include at least one following mutation or mutation group: K14R、K13D、K13A、K30R、K33A、T83A、I100L、 R115H、R143L、R147E、A205K/H207V/K208R/ D210E；H207V/K208R/D210E；R214D/K215A/E216V/N217Q；M243H；M243Q；E267D；T314N and G317E。

SEQ ID NO:8 is as follows:

" mutation (mutation) " or " mutation (mutations) " is defined herein as the one of known amino acid sequence A or multiple amino acid are also possible to " mutation group respectively by one or more other amino acid exchanges, and if particularly pointed out (group of mutations) " or " mutation group (groups of mutations) "." mutation group " or " mutation group " is at this It is defined as the exchange of group in text, such as 3 or 4 from original series amino acid are respectively in specified location by 3 or 4 Other amino acid exchanges.As definition, by following code above-mentioned mutation for identification." X number Z " indicates to be located at " number " position The amino acid " X " of original amino acid be exchanged for amino acid " Z ", and " XNo.Y/X'No.'Z'/X " No. " Z " " is intended to It indicates in the mutation, amino acid " X " at " number " position, the amino acid " X' " in " number ' " position and in " volume Amino acid " X " in number " " position " being exchanged for amino acid " Z ", " Z' " and " Z " simultaneously respectively ".If defining " mutation group Close ", then use " // " to separate and indicate " simultaneous mutation " in the combination, it is otherwise identical as single oblique line "/".

In another typical pattern, variant differs at least two, or at least 1 to 8, usually 2 to 7 above-mentioned mutation or prominent Change group even more typically differs at least 4 to 7 mutation listed above or mutation group.

In another, the variant of SB10 transposase is selected from the variant comprising following mutation combination:

Variant 1:K14R//R214D/K215A/E216V/N217Q；

Variant 2:K33A/R115H//R214D/K215A/E216V/N217Q//M243H；

Variant 3:K14R/K30R//A205K/H207V/K208R/D210E//R214D/ K215A/E216V/ N217Q//M243H；

Variant 4:K13D/K33 Λ/T83A//H207V/K208R/D210E//M243Q；

Variant 5:K13A/K33A//R214D/K215A/E216V/N217Q；

Variant 6:K33A/T83A//R214D/K215A/E216V/N217Q//G317E；

Variant 7:K14R/T83A/M243Q；

Variant 8:K14R/T83A/1100L/M243Q；

Variant 9:K14R/T83A/R143L/M243Q；

Variant 10:K14R/T83A/R147E/M243Q；

Variant 11:K14R/T83A/M243Q/E267D；

Variant 12:K14R/T83A/M243Q/T314N；

Variant 13:K14R/K30R/I100I7/A205K/H207V/K208R/D210E//R214D/K215A/ E216V/N217Q//M243H；

Variant 14:K14R/K30R/R143I7/A205K/H207V/K208R/D210E//R214D/K215A/ E216V/N217Q//M243H；

Variant 15:K14R/K30R/R147E//A205K/H207V/K208R/D210E//R214D/K215A/ E216V/N217Q//M243H；

Variant 16:K14R/K30R//A205K/H207V/K208R/D210E//R214D/K215A/E216V/ N217Q//M243H/E267D；

Variant 17:K14R/K30R//A205K/H207V/K208R/D210E//R214D/K215A/E216V/ N217Q//M243 H/T314N；

Variant 18:K14R/K30R//A205K/H207V/K208R/D210E//R214D/K215A/E216V/ N217Q//M243H/G317E；

Variant 19:K14R/K33A/R1 15H//R214D/K215A/E216V/N217Q//M243H；

Variant 20:K14R/K30R/R147E//A205K/H207V/K208R/D210E//R214D/K215A/ E216V/N217Q//M243H/T314N；

Variant 21:K14R/K30R/R143L//A205K/H207V/K208R/D210E//R214D/K215A/ E216V/N217Q//M243H/E267D；

Variant 22:K14R/K30R/R143L//A205K/H207V/K208R/D210E//R214D/K215A/ E216V/N217Q//M243H/T314N；

Variant 23:K14R/K30R/R143L//A205K/H207V/K208R/D210E//R214D/K215A/ E216V/N217Q//M243H/G317E；

Variant 24:K14R/K33A/R1 15H/R143L//R214D/K215A/E216V/ N217Q//M243H；

Variant 25:K14R/K33A/R1 15H/R147E//R214D/K215A/E216V/ N217Q//M243H；

Variant 26:K14R/K33A/R115H//R214D/K215A/E216V/N217Q//M243H/E267D；

Variant 27:K14R/K33A/R115H//R214D/K215A/E216V/N217Q//M243H/T314N；

Variant 28:K14R/K33A/R1 15H//R214D/K215A/E216V/N217Q//M243H/G317E；

Variant 29:K14R/T83A/M243Q/G317E；

Variant 30:K13A/K33A/T83A//R214D/K215A/E216V/N217Q

In a typical pattern, transposase is SB100X transposase, and variant 27 is marked as in list above.

Immunocyte

Before the amplification of immunocyte as described herein and genetic modification, from the source of individual adaptive immune cell.It answers Work as understanding, can be used any immunocyte source, and they can be self, allogeneic, homology it is of the same race or Xenogenesis.Typical pattern, immunocyte are self or allogeneic.

For example, PBMC can be obtained by any known method, then it is stimulated as CIK cell, such as such as WO Described in 2016/071513, it is integrally incorporated by reference.Then CIK cell can be made to CIK CAR cell. Alternatively, T cell can be obtained by any known method, and it is subsequently used in and generates CAR-T cell.

CAR as described herein either is expressed before or after the gene modification of immunocyte, usually can be made The method described in following activates and expands immunocyte: such as U.S. Patent No. 6,352,694；6,534,055th Number；No. 6,905,680；No. 6,692,964；No. 5,858,358；No. 6,887,466；No. 6,905,681；The No. 7,144,575；No. 7,067,318；No. 7,172,869；No. 7,232,566；No. 7,175,843；5th, No. 883,223；No. 6,905,874；No. 6,797,514；No. 6,867,041；U.S. Patent Application Publication No. No. 20060121005；With WO 2016/071513 (they are integrally incorporated herein by reference).

Treatment use

The immunocyte of CAR as described herein and expression CAR blocking VEGF R-2 and can reduce its activation capacity.Knot It closes and also activates CAR-T cell or CIK CAR cell and immunocyte is stimulated to kill cancer cell.These antibody are better than treating for chemistry The advantages of drug of method, is that they are more specific to the tumour for being overexpressed VEGFR-2.Therefore, this will lead to general cell poison Property and cancer cell chemoresistance reduce.In addition, CAR as described herein has tissue penetration due to their small size.

The present invention covers the cell (such as T cell) transduceed with slow virus carrier (LV) or transfected with transposons.For example, LV or transposons encode CAR, and by antigen recognizing structural domain and CD3- ζ of specific antibodies, CD28,4-1BB or theirs is any Combined intracellular domain combination.Therefore, the T cell of transduction causes the t cell response that CAR is mediated, therefore can help to subtract Few tumour growth and inducing cell killing.

The present invention provides CAR for the specificity of primary T cells to be redirected to the purposes of tumour antigen-VEGFR-2. Therefore, the present invention also provides for stimulating the cell-mediated immune response to target cell group or tissue of T in mammal Method comprising the step of giving the T cell of expression CAR to mammal, wherein CAR includes mutual with predetermined target specificity The bound fraction of effect, the ζ chain part containing such as intracellular domain of people CD3 ζ and costimulatory signal area.

On the one hand, the present invention includes a type of cell therapy, wherein carrying out gene modification to T cell or CIK cell To express the CAR for being directed to VEGFR-2, and CAR-T or CIK-CAR cell infusion is given to the recipient for needing the method.Infusion Cell can kill the intracorporal tumour cell of recipient.Different from antibody therapy, CAR-T and CIK-CAR cell can be in body Interior duplication, this leads to the long-term persistence that lasting tumour can be caused to control.

On the one hand, CAR-T the or CIK-CAR cell as described herein for targeting VEGFR-2 is able to carry out steady internal Cell amplification, and sustainable extended time.On the other hand, CAR-T Cellular evolution as described herein is that specific memory T is thin Born of the same parents can be reactivated to inhibit any other tumour to be formed or grown.It is not intended to be any particular theory, CAR-T cell can be divided into maincenter memory sample once encountered and then eliminated the target cell of expression Surrogate antigen in vivo State.

It is actively or passively immunized in addition, can be by the anti-tumor immune response that the T or CIK cell of CAR modification cause Response.In addition, the immune response that CAR is mediated can be a part of adoptive immunotherapy method, wherein the T of CAR modification is thin Born of the same parents induce antigen-binding portion thereof specific immune response in CAR.For example, VEGFR-2 specific C AR-T or CIK cell initiation pair The specific immune response of the cell of VEGF expression R-2.

On the one hand, the antigen-binding portion thereof of CAR described herein is designed to the particular cancer for the treatment of expression specific antigen Disease.For example, CAR described herein is usually VEGFR-2 specificity, and can be used for treating cancer relevant to VEGFR-2 Disease and illness, such as cancer of pancreas, oophoroma, bladder cancer, breast cancer, lung cancer, hepatocellular carcinoma and colon cancer.

The T cell of CAR modification as described herein is also used as the epidemic disease of mammal Ex vivo immunization and/or in vivo Seedling type.In general, mammal is people.

About Ex vivo immunization, before giving cell to mammal, external generation is at least one of three kinds following: i) Cell amplification, ii) nucleic acid that will encode CAR introduces cell and/or iii) Cell Cryopreservation.

In vitro program is well-known in the art, and is discussed more fully below.In brief, from mammal (usually people) separates cell, and carries out gene modification (i.e. ex vivo transduction or transfection) with the carrier for expressing CAR disclosed herein. The CAR cell modified can be given to mammalian subject to provide treatment benefit.Mammalian subject can be people, and And the cell of CAR modification can be self relative to recipient.Alternatively, cell can be allogeneic relative to recipient , homology is of the same race or xenogenesis.

Program description in vitro amplifying candidate stem cell and progenitor cells is in the beauty being incorporated herein by reference In state's patent the 5th, 199,942, described program can be used for cell as described herein.Other suitable methods be this field Know, therefore the present invention is not limited to any ad hoc approach of cells ex vivo amplification.In brief, the in vitro culture and expansion of T cell Increasing includes: that the CD34+ candidate stem cell and ancestral of (1) from peripheral blood acquisition object or the collection of marrow explant from mammal are thin Born of the same parents；And (2) expand such cell in vitro.In addition to Porcine HGF described in U.S. Patent No. 5,199,942, other The factor such as flt3-L, IL-1, IL-3 and c-kit ligand can be used in culture and amplifying cells.

In addition to other than in terms of Ex vivo immunization using based on the vaccine of cell, the present invention also provides the groups for vivo immunization Object and method are closed, to cause the immune response for being directed to antigen in patient.

Specifically, the T cell of CAR modification as described herein is used to treat the cancer of VEGF expression R-2.In some terms, this Cell described in text is used to treat the patient of the risk of cancer of the VEGF expression R-2 in progress.Therefore, the present invention provides The method of cancer for treating or preventing VEGF expression R-2 comprising have to needing the individual of the method to give treatment The T cell of the CAR as described herein modification of effect amount.

The T cell of CAR modification of the invention can individually be given, or as with diluent and/or with other components such as IL-2 or other cell factors or the pharmaceutical composition of cell mass combination are given.In brief, pharmaceutical composition of the invention can Comprising thin with the target as described herein of one or more drugs or physiologically acceptable carrier, diluent or excipient composition Born of the same parents group.Such composition may include buffer, such as neutral buffered saline, phosphate buffered saline (PBS)；Carbohydrate, such as Portugal Grape sugar, mannose, sucrose or glucan, mannitol；Protein；Polypeptide or amino acid (such as glycine)；Antioxidant；Chelating Agent, such as EDTA or glutathione；Adjuvant (such as aluminium hydroxide) and preservative.Composition of the invention is typically formulated for vein Inside give.

Pharmaceutical composition of the invention can be given in a manner of being suitable for the disease of (or prevention) to be treated.Although can To determine dosage appropriate by clinical test, the amount and frequency given will be by the types of such as patient's states and patient disease It is determined with factors such as seriousness.

When referring to " immune effective dose ", " antitumor effective quantity ", " tumor suppression effective quantity " or " therapeutic dose ", Neng Gouyou Doctor consider patient (individual) age, weight, tumor size, infection or metastasis degree and state individual difference determination to The precise volume for the present composition given.In general, can be with 10⁴To 10⁹A cell/kg weight is usually 10⁵To 10⁶It is a thin Born of the same parents/kg weight dosage, the dosage including all integer values within the scope of those give the medicine comprising T cell as described herein Compositions.T cell composition can also be repeatedly given with these dosage.It can be by using commonly known in immunotherapy Infusion techniques give cell (see, e.g., Rosenberg et al., New Eng.J.of Med.319:1676,1988).It is logical It crosses the disease symptom of monitoring patient and correspondingly adjustment treatment, the technical staff of medical domain can be readily determined particular patient Optimal dose and therapeutic scheme.

Some aspects, it may be necessary to give the T cell of activation to individual, be then followed by blood drawing again and (or carry out single blood sampling Liquid ingredient art), the T cell of the invention from activation, and it is transfused to patient again with the T cell of these activation and amplification.The process can It is multiple with every several Zhou Jinhang.In some terms, can the blood drawing from 10cc to 400cc carry out activating T cell.In some terms, from 20cc, The blood drawing of 30cc, 40cc, 50cc, 60cc, 70cc, 80cc, 90cc or 100cc carry out activating T cell.It is without being bound by theory, it uses This multiple blood drawing/repeatedly infusion scheme can be used for selecting certain T cell groups again.

The composition can be given in any convenient manner, including passes through aerosol sucking, injection, intake, infusion, plant Enter or transplants.Can in subcutaneous, intradermal, tumour, in knot, in marrow, intramuscular, by will in intravenous (i.v.) injection or peritonaeum Composition as described herein gives patient.On the one hand, T cell composition of the invention is given and is suffered from by intradermal or subcutaneous injection Person.On the other hand, T cell composition of the invention usually is given by i.v. injection.The composition of T cell can directly be infused It is mapped in tumour, lymph node or infection site.

In certain aspects of the invention, using method described herein or other methods known in the art, will activation and The cell of amplification, wherein T cell is expanded to treatment level, combine with any amount of associated treatment mode (for example, before, Simultaneously or after) patient is given, the associated treatment mode includes but is not limited to chemotherapy, radiation, immunosuppressor, such as ring Spore rhzomorph, imuran, amethopterin, mycophenolate and FK506, antibody or other immune clearance agent (immunoablative agents), such as CAM PATH, anti-cd 3 antibodies or other antibody therapies, cytotoxin, fludarabine, Cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cell factor and radiation.These Drug inhibition calcium It relies on acid phosphatase calcineurin (cyclosporin and FK506) or inhibits important to the signal of growth factor-induced P70S6 kinases (rapamycin) (Liu et al. people, Cell 66:807-815,1991；Henderson et al., Immun 73:316- 321,1991；Bierer et al., Curr.Opin.Immun 5:763-773,1993).On the other hand, by groups of cells of the invention Object and bone-marrow transplantation are closed, chemotherapeutics such as fludarabine, external beam irradiation treatment (XRT), cyclophosphamide or antibody such as OKT3 are used Or the T cell ablation therapy joint of CAMPATH gives patient (prior to, concurrently with, or after for example).On the other hand, in B cell Cell composition of the invention is given after reagent such as Mabthera that ablation therapy is such as reacted with CD20.Such as, on the one hand, individual can To receive the chemotherapeutic standard care of high dose, autologous peripheral blood stemcell transplant is then carried out.In some terms, after the transfer, it is a Body receives the infusion of the immunocyte of amplification as described herein.On the other hand, the cell of amplification is given before the surgery or later.

The dosage of the above-mentioned treatment of patient to be administrated will be with the definite property and the recipient for the treatment of for treating the patient's condition And change.The scaling that people gives dosage can be carried out according to art-recognized practice.For example, for adult patients, The dosage of CAMPATH will usually be administered once per day for the treatment of usually in the range of 1 to about 100 mg, and continue 1 to 30 day time Section.Typical daily dosage is daily 1 to 10mg, but in some cases, and the up to larger dose of 40mg can be used daily (being described in U.S. Patent No. 6,120,766).

In certain aspects of the invention, the composition comprising CAR-T of the invention can be with stored under refrigeration until use or cold Freeze (and then thaw) until need using.It can prepare and provide the composition in the form in " library " of CAR-T cell, to be used for The therapeutic treatment of VEGFR-2 cancer.

In embodiments of the invention, the cell for being used for cell therapy is provided in kit, and in certain situations Under, cell is substantially the sole component of kit.Kit may include the reagent and material for preparing desired cell.Having In body embodiment, reagent and material include for expanding the primer of desired sequence, nucleotide, suitable buffer or delaying Rush reagent, salt etc., and in some cases, reagent include carrier and/or coding CAR as described herein DNA and/or Its controlling element.

In a particular embodiment, have in kit one or more suitable for extracting one or more samples from individual Device.The device can be syringe, scalpel etc..

It is of the invention in some cases, in addition to cell therapy embodiment, kit further includes the second cancer therapy, all Such as such as chemotherapy, hormonotherapy and/or immunotherapy.Kit can be customized for the particular cancers of individual, and tried Agent box includes corresponding second cancer therapy for individual.

EXPERIMENTAL EXAMPLE

The present invention is described in further detail by reference to following EXPERIMENTAL EXAMPLE.There is provided what these embodiments were merely to illustrate Purpose, and unless otherwise stated, be not intended to be limiting.Therefore, the present invention should not be interpreted in any way as being limited to following Embodiment, but should be interpreted to cover due to introduction provided herein and become apparent any and all variations.

Following embodiment does not include the detailed description of conventional method, the building of the conventional method such as carrier and plasmid, The gene of coding polypeptide is inserted into examples of such carriers and plasmid, or plasmid is introduced into those used in host cell.Such side Method be well-known to those of ordinary skill in the art those and many publications (including Sambrook, J., Fritsch, E.F.and Maniatis, T. (1989), Molecular Cloning:A Laboratory Manual (molecular cloning: experiment Room handbook), 2nd edition, Cold Spring Harbor Laboratory Press) in be described.

It is not described any further, it is believed that preceding description and following illustrative implementation can be used in those of ordinary skill in the art Example prepares and using the compound of the present invention and implements method claimed.Therefore, following embodiment points out this The typical pattern of invention, and should not be construed in any way as limiting remainder of this disclosure.

It was found that summarizing

Human cancer such as breast cancer, cancer of pancreas, colorectal cancer and non-small cell adenocarcinoma of lung of the VEGFR-2 in many types Middle overexpression.In certain animal models, by antibody target VEGFR-2 can reduce/prevent angiogenesis slow down it is swollen Tumor progress.Antibody is generated to target VEGFR-2.AB1 is the Camelidae separated from the yamma library of entire carcinoma cell immunization Single domain antibody.Antibody is specifically bound with high-affinity and VEGFR-2, and inhibit the cancer cell of VEGF expression R-2 in vitro Proliferation.

AB1 Camelidae antibodies target the extracellular domain of VEGFR-2 and by the VEGFR2/Fc of recombination to America Camel is immunized and generates.It generates and screening phage display library is to identify the antibody for having high binding affinity to VEGFR-2. Select antibody is expressed in E.coli. BL21 (DE3) pT7 system.It is described by SEC, LC-MS peptide mapping and ELISA The feature of antibody purification.

Engineering CAR-T cell is anti-to express the Camelidae combined with CD28 and 4-1BB costimulatory molecules and CD3 ζ chain VEGFR-2 antibody (AB1).The cell line of anti-VEGFR-2 CAR-T cell and VEGF expression R-2 are incubated for altogether to be caused as passed through LDH The measured dose dependent target cell toxicity of release.In addition, because detect in cell culture medium high-caliber IL-2 and IFN-γ, it is thus identified that T cell activity.These are the result shows that anti-VEGFR-2 CAR-T can be used for being directly targeted VEGF expression R-2's Tumour.

Embodiment 1: the generation of anti-VEGFR-2 antibody

In order to generate the Camelidae single domain antibody for the extracellular domain for targeting VEGFR-2, with the VEGFR-2/Fc of recombination Immune yamma.It generates and screening phage display library is to identify that the single domain for having high binding affinity to VEGFR-2 is anti- Body.

In order to generate targeting VEGFR-2 extracellular domain people's single domain antibody, screen the library people VH to identify pair VEGFR-2 has the single domain antibody of high binding affinity.

By fusion partner sequence MKAIFVLKGSLDRDPEFDDE (SEQ ID NO:71) be added to SEQ ID NO:2 and The N-terminal of SEQ ID NO:11 (AB1 and AB2) sequence, will pass through albumen expressed in accumulation inclusion body and effectively Simplify protein purification and renaturation process to improve the yield of antibody.

It prepares and further studies 4 kinds of antibody.Selected antibody is expressed in E.coli.BL21 (DE3) pT7 system.This Two (AB2 (SEQ ID NO:13) and AB3 (SEQ ID NO:21)) in a little antibody are based on human antibody bracket, and SEQ ID NO:7 and 27 (AB1 and AB4) the two be yamma source.These antibody displays go out enough quality to be considered special The binding kinetics (table 1) of the potential candidate of property combination VEGFR-2.

The feature of 1. antibody of table describes